var title_f24_31_25072="Babcock clamp";
var content_f24_31_25072=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Babcock clamp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 417px; height: 485px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The rounded grasp of the Babcock clamp is useful for handling of the fallopian tube.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_31_25072=[""].join("\n");
var outline_f24_31_25072=null;
var title_f24_31_25073="Conjunctival neoplasia";
var content_f24_31_25073=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Conjunctival neoplasia with corneal extension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Image created by Christopher J. Rapuano, MD. Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_31_25073=[""].join("\n");
var outline_f24_31_25073=null;
var title_f24_31_25074="Indirect inguinal hernia B";
var content_f24_31_25074=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Indirect inguinal hernia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This transverse section of the anterior abdominal wall illustrates the herniation of peritoneal contents into the inguinal canal through the internal inguinal ring, along the course of the spermatic cord.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from O'Rahilly. Abdominal walls. In: Basic Human Anatomy, W.B. Saunders Company, Philadelphia 1983. p.230.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_31_25074=[""].join("\n");
var outline_f24_31_25074=null;
var title_f24_31_25075="Solitary enchondroma sites";
var content_f24_31_25075=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skeletal distribution of solitary enchondroma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 247px; height: 605px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_31_25075=[""].join("\n");
var outline_f24_31_25075=null;
var title_f24_31_25076="Tobramycin (ophthalmic): Patient drug information";
var content_f24_31_25076=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tobramycin (ophthalmic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/20/41283?source=see_link\">",
"     see \"Tobramycin (ophthalmic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/59/35762?source=see_link\">",
"     see \"Tobramycin (ophthalmic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9600316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AK-Tob&trade;;",
"     </li>",
"     <li>",
"      Tobrex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9600317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PMS-Tobramycin;",
"     </li>",
"     <li>",
"      Sandoz-Tobramycin;",
"     </li>",
"     <li>",
"      Tobrex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat eye infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703044",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tobramycin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have hearing loss, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705323",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All eye products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694635",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not wear contact lenses at any time while using this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Eye drops:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705387",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Eye ointment:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695513",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place drug inside the lower lid. Close the eye for 1 to 2 minutes. Roll eyeball around.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695617",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 10 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12323 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-B28792CD2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_31_25076=[""].join("\n");
var outline_f24_31_25076=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600316\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600317\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024689\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024688\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024693\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024694\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024696\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024691\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024692\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024697\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024698\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/20/41283?source=related_link\">",
"      Tobramycin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/59/35762?source=related_link\">",
"      Tobramycin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/27/13753?source=related_link\">",
"      Tobramycin (systemic therapy and oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/45/15061?source=related_link\">",
"      Tobramycin (systemic therapy and oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/54/15209?source=related_link\">",
"      Tobramycin (systemic therapy and oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_31_25077="Heme synthesis and porphyria";
var content_f24_31_25077=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F68187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F68187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Heme synthesis and the porphyrias",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 442px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of heme synthesis and the enzymatic defects in the porphyrias, beginning with the formation of ALA from succinyl CoA and glycine. The enzymatic defect in each porphyria is shown by a red broken line. In patients, the substrate for the defective enzyme accumulates and is excreted into urine or stool.",
"    <div class=\"footnotes\">",
"     ALA: delta-aminolevulinic acid; PBG: porphobilinogen; HMB: hydroxymethylbilane; Uro'gen: uroporphyrinogen; copro'gen: coproporphyrinogen; Proto'gen: protoporphyrinogen; XLPP: X-linked protoporphyria; XLSA: X-linked sideroblastic anemia; ADP: ALA dehydratase porphyria; AIP: acute intermittent porphyria; CEP: congenital erythropoietic porphyria; PCT: porphyria cutanea tarda; HEP: hepatoerythropoietic porphyria; HCP: hereditary coproporphyria; VP: variegate porphyria; EPP: erythropoietic protoporphyria.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_31_25077=[""].join("\n");
var outline_f24_31_25077=null;
var title_f24_31_25078="Clinical manifestations and diagnosis of familial Mediterranean fever";
var content_f24_31_25078=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of familial Mediterranean fever",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/31/25078/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/31/25078/contributors\">",
"     Peter M Rosenberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/31/25078/contributors\">",
"     Stephen E Goldfinger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/31/25078/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/31/25078/contributors\">",
"     Lawrence S Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/31/25078/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/31/25078/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/31/25078/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 17, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial Mediterranean fever (FMF) is a disorder characterized by sporadic, paroxysmal attacks of fever and serosal inflammation. It is inherited as an autosomal recessive trait. The cloning of the FMF gene (MEFV) promises to enhance our understanding of the sequence of events leading to the diverse clinical manifestations of this disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32261?source=see_link\">",
"     \"Pathophysiology of familial Mediterranean fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    FMF has been described primarily in several ethnic groups originating in the Mediterranean littoral: Sephardic Jews, Armenians, Turks, North Africans, Arabs, and, less commonly, Greeks and Italians. However, the disease is not restricted to these groups. In the United States, for example, FMF is frequently encountered in Ashkenazi Jews. Because cases of FMF have been diagnosed in a wide variety of ethnic groups, ancestry should not be used to rule out the diagnosis if other clinical characteristics are present.",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of FMF will be reviewed here. The management of this disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8247?source=see_link\">",
"     \"Management of familial Mediterranean fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with familial Mediterranean fever (FMF) experience their first attack in early childhood; in 65 percent of cases, the initial attack occurs before the age of 10, and in 90 percent before the age of 20 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25078/abstract/1\">",
"     1",
"    </a>",
"    ]. The typical manifestations of the disease are recurrent attacks of severe pain (due to serositis at one or more sites) and fever, lasting one to three days, and then resolving spontaneously. In between attacks, patients feel entirely well. Pain and fever are usually abrupt and reach their peak soon after onset. Many patients have a stereotypic prodrome before their attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25078/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of attacks is highly variable, even in a given patient, and it is unusual for a patient to describe a consistent triggering event. Vigorous exercise is regarded as an attack trigger by a few patients. Others may describe exposure to cold, emotional stress, or menstruation as preludes to an attack, but such reports are rare and hard to document with certainty. Attacks tend to abate during the second half of pregnancy, probably because of hormonal changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Peritonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ninety-five percent of patients with FMF have painful attacks localized to the abdomen, which is usually the dominant manifestation of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25078/abstract/1\">",
"     1",
"    </a>",
"    ]. Pain and tenderness may initially be focal, and then progress to become more generalized. Guarding, rebound tenderness, rigidity, and an adynamic ileus are often present. These findings so closely resemble those of an acute surgical abdomen that an exploratory laparotomy is sometimes performed, during which an uninflamed appendix is usually removed.",
"   </p>",
"   <p>",
"    Recurrent attacks of peritonitis may lead to adhesions, with the potential for causing small bowel obstruction. Pelvic adhesions can reduce fertility in female patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pleuritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Painful FMF attacks may also be localized to the chest. They may reflect either direct inflammation of the pleura or referred pain from subdiaphragmatic inflammation. Pleural inflammation typically manifests as unilateral pleuritic chest pain with a small, transient pleural effusion. Like episodes of peritonitis, these episodes usually resolve within three days, but may last up to one week.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Synovitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthritis is another common manifestation of FMF; its incidence correlates with the patient's ethnicity. North Africans, for example, are most prone to severe, recurrent attacks or arthritis, while Armenians and Ashkenazi Jews are relatively spared [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25078/abstract/3\">",
"     3",
"    </a>",
"    ]. The arthritis is most often monoarticular or oligoarticular, and the joints most often affected are the knee, ankle, hip, and elbow, in order of frequency. Occasionally, patients present with migratory polyarthritis resembling acute rheumatic fever.",
"   </p>",
"   <p>",
"    Joint effusions are common during attacks of synovitis. Analysis of the fluid reveals 200 to 1,000,000 white blood",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    with a predominance of neutrophils, and an elevated total protein concentration.",
"   </p>",
"   <p>",
"    The arthritis often occurs independently of the other manifestations of FMF, and may last for weeks to months. The synovitis usually resolves completely without joint destruction. However, severely protracted cases can result in permanent deformity, functional limitation, osteoporosis, and even aseptic necrosis.",
"   </p>",
"   <p>",
"    In one study of 256 FMF patients, the prevalence of sacroiliitis was 7 percent. Of the patients with FMF and sacroiliitis, the prevalence of a M694V mutation on the pyrin gene and HLA-B27 haplotype were 94 and 47 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25078/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Erysipelas-like skin lesion",
"    </span>",
"    &nbsp;&mdash;&nbsp;An erysipelas-like skin lesion is reported in 7 to 40 percent of FMF patients and more commonly occurs among patients in the eastern Mediterranean region. The lesion is tender, raised, and erythematous lesion (mimicking acute infectious cellulitis), occurring unilaterally on the lower leg, ankle or foot. Its overall area is about 10 to 15 cm",
"    <sup>",
"     2",
"    </sup>",
"    . The lesion may be the presenting feature of FMF in children. Recovery is spontaneous and there is no need for antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other acute manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inflammatory process of FMF may manifest itself in several other organ systems:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pericarditis has been described in several patients with FMF (estimated incidence 0.7 percent), and in one case has caused cardiac tamponade [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25078/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Self-limited orchitis and recurrent aseptic meningitis also can occur.",
"     </li>",
"     <li>",
"      A few patients with FMF have reported protracted bouts of febrile myalgia that may last as long as one month, and sometimes involve the abdominal muscles [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25078/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An increased incidence of some vasculitides, such as polyarteritis nodosa and Henoch-Sch&ouml;nlein purpura (IgA vasculitis) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link&amp;anchor=H11#H11\">",
"       \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\", section on 'Clinical manifestations in adults'",
"      </a>",
"      ), has been described [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25078/abstract/7\">",
"       7",
"      </a>",
"      ]. Kidney involvement with these processes may be particularly common.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute attacks of FMF are accompanied by elevation of many of the serum markers of systemic inflammation. Leukocytosis with a predominance of neutrophils is common, as is an elevation in the erythrocyte sedimentation rate (ESR) and other acute phase reactants, including beta-2 microglobulin, C-reactive protein (CRP), SAA (serum amyloid protein), and fibrinogen.",
"   </p>",
"   <p>",
"    The presence of otherwise unexplained proteinuria in between attacks may be seen in renal amyloidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/29/13784?source=see_link\">",
"     \"Renal amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Long-term complications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Secondary (AA) amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the inflammatory attacks of untreated FMF are the cause of much morbidity, the major source of mortality in this disease is progressive secondary (AA) amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25078/abstract/8\">",
"     8",
"    </a>",
"    ]. Before the advent of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    , amyloidosis occurred in approximately 30 percent of Sephardic Jews and 60 percent of Turks with FMF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25078/abstract/3\">",
"     3",
"    </a>",
"    ]. Amyloidosis is much less common in Ashkenazi Jews and FMF patients living in America, including those of Armenian ancestry [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25078/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence has decreased markedly with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    , although amyloidosis still remains a substantial problem in Turkey and Armenia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25078/abstract/10\">",
"     10",
"    </a>",
"    ]. Possible causes include a delay in diagnosis, unavailability of colchicine, and incomplete adherence to treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8247?source=see_link\">",
"     \"Management of familial Mediterranean fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The amyloid deposited in FMF consists of amyloid A (AA), which is derived from serum amyloid A protein, an acute phase reactant that rises markedly during acute attacks of FMF. It is unclear whether the deposition of amyloid is due solely to the by-products of recurrent systemic inflammation or whether there is a contribution from the underlying genetic defect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30086?source=see_link\">",
"     \"Pathogenesis of secondary (AA) amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The latter possibility is suggested by reports of a few patients who developed amyloidosis without prior, clinically apparent inflammatory attacks (so-called FMF type II) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25078/abstract/11\">",
"     11",
"    </a>",
"    ]. Observers have repeatedly noted the poor correlation between the severity or frequency of attacks of FMF and the extent of amyloidosis in individual patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32261?source=see_link\">",
"     \"Pathophysiology of familial Mediterranean fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, analysis of the phenotypic expressions of the two most frequent mutations of the FMF gene, V726A and M694V, suggested that amyloidosis and severe arthritis are much more frequently observed with the latter defect [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25078/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Other modifying proteins have also been implicated. Patients without amyloidosis are more likely to have beta and gamma alleles of type 1 serum amyloid A protein suggesting that these alleles may be protective [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25078/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Amyloid A deposition occurs in the kidney, spleen, liver, and gut. Renal involvement is the dominant feature of FMF-related amyloidosis. It begins insidiously, causing proteinuria, then progresses to symptomatic nephrotic syndrome, and eventually ends in renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/29/13784?source=see_link\">",
"     \"Renal amyloidosis\"",
"    </a>",
"    .) The natural history of amyloidotic nephropathy in FMF is such that end-stage renal disease develops from 2 to 13 years after the onset of proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25078/abstract/1\">",
"     1",
"    </a>",
"    ]. Malabsorption due to intestinal amyloidosis has been described.",
"   </p>",
"   <p>",
"    The diagnosis of amyloidosis in FMF may be made most expediently and safely by rectal or bone marrow biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25078/abstract/14\">",
"     14",
"    </a>",
"    ]. However, the presence of persistent proteinuria in a patient with known FMF that has not been well controlled by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    is so suggestive of amyloidosis that a biopsy is often not necessary for diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other complications that were primarily seen before the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    included depression, opiate addiction, and poor school and job performance. Subclinical cardiac autonomic dysfunction, apparently unrelated to amyloidosis, may be present in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25078/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of familial Mediterranean fever (FMF) is based upon three factors: typical clinical manifestations, a positive response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    therapy, and genetic testing, although currently available tests do not detect all mutations associated with FMF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Clinical diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical diagnosis of FMF is based upon both the characteristic clinical features and the exclusion of other illnesses. Major criteria for the clinical diagnosis of FMF are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intermittent episodes of fever with robust interim health",
"     </li>",
"     <li>",
"      Concomitant serositis with abdominal pain and tenderness or pleuritis",
"     </li>",
"     <li>",
"      Absence of an alternative cause",
"     </li>",
"     <li>",
"      Responsiveness to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"     </li>",
"     <li>",
"      Monoarthritis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following findings may or may not be present:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Amyloidosis",
"     </li>",
"     <li>",
"      Positive family history",
"     </li>",
"     <li>",
"      Mediterranean ancestry",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical criteria for the diagnosis in combination with a classification tree format have been proposed; in one report, these criteria had a sensitivity as high as 95 percent and a specificity as high as 99 percent for the diagnosis (",
"    <a class=\"graphic graphic_table graphicRef67666 \" href=\"UTD.htm?17/51/18236\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef77816 \" href=\"UTD.htm?29/56/30606\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25078/abstract/16\">",
"     16",
"    </a>",
"    ]. There are, however, two potential limitations to this study: the gold standard for the diagnosis of FMF was based upon clinical findings; and the findings in the population studied at this hospital may not be applicable to other groups of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple other disease processes may closely resemble FMF and must be excluded before making the clinical diagnosis of FMF. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Surgical emergencies (appendicitis, intussusception, perforated peptic ulcer, etc)",
"     </li>",
"     <li>",
"      Hereditary angioedema",
"     </li>",
"     <li>",
"      Acute intermittent porphyria",
"     </li>",
"     <li>",
"      Relapsing pancreatitis",
"     </li>",
"     <li>",
"      Systemic lupus erythematosus and vasculitis",
"     </li>",
"     <li>",
"      Hypertriglyceridemia",
"     </li>",
"     <li>",
"      Abdominal epilepsy and abdominal migraine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The differential diagnosis of FMF also includes other rare hereditary periodic fever syndromes: tumor necrosis factor receptor-1-associated periodic syndrome (TRAPS), hyper-IgD syndrome, Muckle-Wells syndrome, and familial cold autoinflammatory syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25078/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=see_link\">",
"     \"Periodic fever syndromes and other autoinflammatory diseases: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24487?source=see_link\">",
"     \"Cryopyrin-associated periodic syndromes and related disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cloning of the FMF gene (MEFV) in 1997 makes genetic testing possible [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25078/abstract/18\">",
"     18",
"    </a>",
"    ] and testing for many of the known mutations is currently available at some commercial laboratories (Center for Human Genetics, Boston, MA, 617-638-7083, and Westwood Clinical Laboratory, Los Angeles, CA, 310-825-8080). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32261?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathophysiology of familial Mediterranean fever\", section on 'The FMF gene'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since FMF is inherited as an autosomal recessive trait, one would expect that two mutations would be required for clinical disease. However, some patients have only one identifiable mutation and some have no identifiable mutations.",
"   </p>",
"   <p>",
"    A pilot study of a rapid assay correctly identified mutations in the MEFV gene in 82 of 82 patients in whom the diagnosis was confirmed by DNA sequencing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25078/abstract/19\">",
"     19",
"    </a>",
"    ]. However, known mutations have not been identified in as many as 45 percent of patients with clinical FMF in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25078/abstract/20\">",
"     20",
"    </a>",
"    ] and in 28 percent of Jewish and Arab children in Israel [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25078/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a 1998 study from the National Institutes of Health, an MEFV mutation was identified in 47 of 86 patients who fulfilled the generally accepted criteria for the diagnosis of FMF: 24 were apparent homozygotes whereas only a single mutation could be identified in the other 23 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25078/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2009 study from the NIH using complete MEFV sequencing identified 46 patients with clinical FMF who carried only one high penetrance MEFV mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25078/abstract/22\">",
"     22",
"    </a>",
"    ]. The authors suggested that, with current technology, detection of a single mutation in patients with typical clinical manifestations is sufficient for the diagnosis of FMF and the initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    therapy. Active research is aimed at identifying modifier genes at new susceptibility loci.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Familial Mediterranean fever (FMF) is a disorder characterized by sporadic, paroxysmal attacks of fever and serosal inflammation. It is inherited as an autosomal recessive trait. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      FMF has been described primarily in several ethnic groups originating in the Mediterranean littoral: Sephardic Jews, Armenians, Turks, North Africans, Arabs, and, less commonly, Greeks and Italians. However, the disease is not restricted to these groups. In the United States, for example, FMF is frequently encountered in Ashkenazi Jews. Because cases of FMF have been diagnosed in a wide variety of ethnic groups, ancestry should not be used to rule out the diagnosis if other clinical characteristics are present. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with FMF experience their first attack in early childhood; in 65 percent of cases, the initial attack occurs before the age of 10, and in 90 percent before the age of 20. The typical manifestations of the disease are recurrent attacks of severe pain (due to serositis at one or more sites) and fever, lasting one to three days, and then resolving spontaneously. In between attacks, patients feel entirely well. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute attacks of FMF are accompanied by elevation in many of the serum markers of systemic inflammation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Laboratory abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is usually made on clinical grounds and confirmed by a response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      . Genetic testing is also available but an appreciable proportion of patients with clinical FMF have only one or no MEFV mutations. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple other disease processes may closely resemble FMF and must be excluded before making the diagnosis of FMF. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25078/abstract/1\">",
"      Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 1967; 43:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25078/abstract/2\">",
"      Lidar M, Yaqubov M, Zaks N, et al. The prodrome: a prominent yet overlooked pre-attack manifestation of familial Mediterranean fever. J Rheumatol 2006; 33:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25078/abstract/3\">",
"      Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet 1998; 351:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25078/abstract/4\">",
"      Ka��ifo��lu T, Cali��ir C, Cansu DU, Korkmaz C. The frequency of sacroiliitis in familial Mediterranean fever and the role of HLA-B27 and MEFV mutations in the development of sacroiliitis. Clin Rheumatol 2009; 28:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25078/abstract/5\">",
"      Kees S, Langevitz P, Zemer D, et al. Attacks of pericarditis as a manifestation of familial Mediterranean fever (FMF). QJM 1997; 90:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25078/abstract/6\">",
"      Ertekin V, Selimo��lu MA, Alp H, Yilmaz N. Familial Mediterranean fever protracted febrile myalgia in children: report of two cases. Rheumatol Int 2005; 25:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25078/abstract/7\">",
"      Ozen S, Ben-Chetrit E, Bakkaloglu A, et al. Polyarteritis nodosa in patients with Familial Mediterranean Fever (FMF): a concomitant disease or a feature of FMF? Semin Arthritis Rheum 2001; 30:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25078/abstract/8\">",
"      van der Hilst JC, Simon A, Drenth JP. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med 2005; 5:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25078/abstract/9\">",
"      Pras M. Amyloidosis of familial mediterranean fever and the MEFV gene. Amyloid 2000; 7:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25078/abstract/10\">",
"      Tunca M, Akar S, Onen F, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 2005; 84:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25078/abstract/11\">",
"      HELLER H, SOHAR E, GAFNI J, HELLER J. Amyloidosis in familial Mediterranean fever. An independent genetically determined character. Arch Intern Med 1961; 107:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25078/abstract/12\">",
"      Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell 1997; 90:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25078/abstract/13\">",
"      Medlej-Hashim M, Delague V, Chouery E, et al. Amyloidosis in familial Mediterranean fever patients: correlation with MEFV genotype and SAA1 and MICA polymorphisms effects. BMC Med Genet 2004; 5:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25078/abstract/14\">",
"      Sungur C, Sungur A, Ruacan S, et al. Diagnostic value of bone marrow biopsy in patients with renal disease secondary to familial Mediterranean fever. Kidney Int 1993; 44:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25078/abstract/15\">",
"      Rozenbaum M, Naschitz JE, Yudashkin M, et al. Cardiovascular autonomic dysfunction in familial Mediterranean fever. J Rheumatol 2002; 29:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25078/abstract/16\">",
"      Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997; 40:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25078/abstract/17\">",
"      Drenth JP, van der Meer JW. Hereditary periodic fever. N Engl J Med 2001; 345:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25078/abstract/18\">",
"      Babior BM, Matzner Y. The familial Mediterranean fever gene--cloned at last. N Engl J Med 1997; 337:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25078/abstract/19\">",
"      Eisenberg S, Aksentijevich I, Deng Z, et al. Diagnosis of familial Mediterranean fever by a molecular genetics method. Ann Intern Med 1998; 129:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25078/abstract/20\">",
"      Samuels J, Aksentijevich I, Torosyan Y, et al. Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine (Baltimore) 1998; 77:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25078/abstract/21\">",
"      Padeh S, Shinar Y, Pras E, et al. Clinical and diagnostic value of genetic testing in 216 Israeli children with Familial Mediterranean fever. J Rheumatol 2003; 30:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25078/abstract/22\">",
"      Booty MG, Chae JJ, Masters SL, et al. Familial Mediterranean fever with a single MEFV mutation: where is the second hit? Arthritis Rheum 2009; 60:1851.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2635 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-9A4DD99832-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_31_25078=[""].join("\n");
var outline_f24_31_25078=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Peritonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pleuritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Synovitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Erysipelas-like skin lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other acute manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Long-term complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Secondary (AA) amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Clinical diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2635\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2635|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?29/56/30606\" title=\"algorithm 1\">",
"      Classification tree dx FMF1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2635|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/51/18236\" title=\"table 1\">",
"      Detailed criteria for the diagnosis of FMF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24487?source=related_link\">",
"      Cryopyrin-associated periodic syndromes and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8247?source=related_link\">",
"      Management of familial Mediterranean fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30086?source=related_link\">",
"      Pathogenesis of secondary (AA) amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32261?source=related_link\">",
"      Pathophysiology of familial Mediterranean fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=related_link\">",
"      Periodic fever syndromes and other autoinflammatory diseases: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/29/13784?source=related_link\">",
"      Renal amyloidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_31_25079="Felbamate: Drug information";
var content_f24_31_25079=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Felbamate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/1/12310?source=see_link\">",
"    see \"Felbamate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/25/28055?source=see_link\">",
"    see \"Felbamate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F170122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Felbatol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F170155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticonvulsant, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F170125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anticonvulsant, monotherapy:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Initial:",
"     </i>",
"     1200 mg/day in divided doses 3 or 4 times/day; titrate previously untreated patients under close clinical supervision, increasing the dosage in 600 mg increments every 2 weeks to 2400 mg/day based on clinical response and thereafter to 3600 mg/day if clinically indicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Conversion to monotherapy:",
"     </i>",
"     Initiate at 1200 mg/day in divided doses 3 or 4 times/day, reduce the dosage of the concomitant anticonvulsant(s) by 33% at the initiation of felbamate therapy; at week 2, increase the felbamate dosage to 2400 mg/day while reducing the dosage of the other anticonvulsant(s) up to an additional 33% of their original dosage; at week 3, increase the felbamate dosage up to 3600 mg/day and continue to reduce the dosage of the other anticonvulsant(s) as clinically indicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anticonvulsant, adjunctive therapy:",
"     </b>",
"     Oral: Initial: 1200 mg/day in divided doses 3 or 4 times/day; increase once per week by 1200 mg/day increments up to 3600 mg/day in divided doses 3 or 4 times/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose of concomitant carbamazepine, phenobarbital, phenytoin, or valproic acid should be decreased by 20% when initiating felbamate therapy.  Further dosage reductions may be necessary as dose of felbamate is increased.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F170142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/25/28055?source=see_link\">",
"      see \"Felbamate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anticonvulsant, monotherapy:",
"     </b>",
"     Oral: Children &gt;14 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adjunctive therapy:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-14 years with Lennox-Gastaut syndrome: Initial: 15 mg/kg/day in divided doses 3 or 4 times/day; increase once per week by 15 mg/kg/day increments up to 45 mg/kg/day in divided doses 3 or 4 times/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;14 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose of concomitant carbamazepine, phenobarbital, phenytoin, or valproic acid should be decreased by 20% when initiating felbamate therapy.  Further dosage reductions may be necessary as dose of felbamate is increased.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F170126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F170127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution; reduce initial and maintenance doses by 50%.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14456066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F170098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 600 mg/5 mL (240 mL, 473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Felbatol&reg;: 600 mg/5 mL (240 mL, 960 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 400 mg, 600 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Felbatol&reg;: 400 mg, 600 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F170082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11233759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A patient &ldquo;informed consent&rdquo; form should be completed and signed by the patient and physician. Copies are available from MEDA Pharmaceuticals by calling 800-526-3840.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F13114473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM263034.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM263034.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F170103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food.  Shake suspension prior to use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F170102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monotherapy or adjunctive therapy in the treatment of partial seizures (with and without generalization); adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome; not indicated for use as first-line treatment",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F170153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence (children 48%; adults 19%), headache (children 7%; adults 7% to 37%), fever (children 23%; adults 3%), dizziness (18%), insomnia (9% to 18%), fatigue (7% to 17%), nervousness (children 16%; adults 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Purpura (children 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia (children 55%; adults 19%), vomiting (children 39%; adults 9% to 17%), nausea (children 7%; adults 34%), dyspepsia (9% to 12%), constipation (7% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory infection (children 45%; adults 5% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (3%), facial edema (3%), palpitation (&ge;1%), tachycardia (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Abnormal thinking (children 7%), ataxia (children 7%; adults 4%), emotional lability (children 7%),  anxiety (5%), depression (5%), stupor (3%), malaise (&ge;1%), agitation (&ge;1%), psychological disturbances (&ge;1%), aggressive reaction (&ge;1%), euphoria (&le;1%), hallucination (&le;1%), migraine (&le;1%), suicide attempt (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Skin rash (children 10%; adults 3% to 4%), acne (3%), pruritus (&ge;1%), bullous eruption (&le;1%), urticaria (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine and metabolic: Hypophosphatemia (&le;1% to 3%), intramenstrual bleeding (3%), hypokalemia (&le;1%), hyponatremia (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Hiccup (children 10%), weight loss (children 7%; adults 3%), taste perversion (6%), abdominal pain (5%), diarrhea (5%), xerostomia (3%), weight gain (&ge;1%), appetite increased (&le;1%), esophagitis (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia (children 7%; adults &le;1%), granulocytopenia (&le;1%), leukocytosis (&le;1%), lymphadenopathy (&le;1%), thrombocytopenia (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver function tests increased (1% to 5%), alkaline phosphatase increased (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Abnormal gait (children 10%; adults 5%), pain (children 7%), tremor (6%), paresthesia (4%), myalgia (3%),  weakness (&ge;1%), dystonia (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Miosis (children 7%), diplopia (3% to 6%), abnormal vision (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic:  Otitis media (children 10%; adults 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (children 10%; adults 3%), cough (children 7%), rhinitis (7%), sinusitis (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (&ge;1%), LDH increased (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute renal failure, agranulocytosis, allergic reaction, alopecia, anaphylactoid reaction, anemia, aplastic anemia, atrial arrhythmia, atrial fibrillation, bradycardia, cardiac arrest, cardiac failure, cerebrovascular disorder, cerebral edema, choreoathetosis, coagulation disorder, coma, concentration impaired, confusion, CPK increased, delusion, diaphoresis, DIC, dysphagia, dyspnea, dysarthria, dyskinesia, dysuria, embolism, encephalopathy, enteritis, eosinophilia, epistaxis, extrapyramidal disorder, flushing, gastric ulcer, gastritis, gastroesophageal reflux, GI hemorrhage, gingival bleeding, glossitis, hematemesis, hematuria, hemolytic anemia, Henoch-Sch&ouml;nlein vasculitis, hepatic failure, hepatitis, hepatorenal syndrome, hyperammonemia, hyper-/hypoglycemia, hyper-/hypotension, hypernatremia, hypocalcemia, hypomagnesemia, hypoxia,  ileus, ischemic necrosis, jaundice, manic reaction, mononeuritis, nephrosis, nystagmus, pancreatitis, pancytopenia, paralysis, paranoid reaction, peripheral ischemia, photosensitivity, platelet disorder, pleural effusion, pneumonitis, psychosis, pulmonary hemorrhage, rectal hemorrhage, renal function abnormal, respiratory depression, rhabdomyolysis, SIADH, status epilepticus, Stevens-Johnson syndrome, sudden death, suicidal behavior/ideation, SVT, thrombophlebitis, torsade de pointes, toxic epidermal necrolysis, ulcerative stomatitis, urinary retention, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F170106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to felbamate or any component of the formulation; known sensitivity to other carbamates; history of any blood dyscrasia or hepatic dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F170086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aplastic anemia:",
"     <b>",
"      [U.S. Boxed Warning]: Felbamate is associated with a significant increased risk of aplastic anemia.",
"     </b>",
"     Risk may be more than 100 fold greater than in untreated population. Current estimates of fatality are 20% to 30%, but higher rates (up to 70%) have been reported in the past. Aplastic anemia can develop at any point during therapy and for an unknown period of time after discontinuation of therapy. It is not known if dose, duration therapy, or concomitant medication use affects risk. Routine blood monitoring may be helpful in detecting hematologic changes before any clinical onset of signs/symptoms of the disease, however, aplastic anemia often develops without any prior indication or warnings. Discontinue use if any evidence of bone-marrow suppression occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic failure:",
"     <b>",
"      [U.S. Boxed Warning]: Has been associated with rare cases of hepatic failure (estimated &gt;6 cases per 75,000 patients per year).",
"     </b>",
"     Of the cases reported in the literature, 67% have resulted in fatality or liver transplant. Onset may or may not be preceded by prodromal symptoms.  It is not known whether dose, duration of therapy, or concomitant medication use affects risk. Monitoring of serum transaminases has not been demonstrated to prevent serious hepatic injury, however, early diagnosis and drug withdrawal may improve the likelihood of recovery.  Obtain baseline transaminase levels and periodically thereafter; discontinue use if transaminase levels increase to &ge;2 times the upper limit of normal or with signs/symptoms suggesting hepatic failure. Therapy should not be initiated or reintroduced in patients with evidence of hepatic damage or who discontinue use for any reason.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; half-life may be increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use:  Not indicated for use as a first-line antiepileptic treatment; only recommended in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F170150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2E1 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F170091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Felbamate. Felbamate may increase the serum concentration of Barbiturates. Management: Monitor for elevated barbiturate concentrations/toxicity if felbamate is initiated/dose increased, or reduced concentrations/effects if felbamate is discontinued/dose decreased. Refer to phenobarbital dosing guidelines for patients receiving that agent.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Felbamate. Felbamate may decrease the serum concentration of CarBAMazepine. Management: In patients receiving carbamazepine, initiate felbamate at 1200 mg/day in divided doses 3-4 times daily while reducing carbamazepine dose by 20%.  Monitor for reduced concentrations/effects of both drugs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Felbamate may decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use of a nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Felbamate may decrease the serum concentration of Contraceptives (Progestins).  Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Felbamate may increase the serum concentration of Divalproex.  Management: In patients receiving divalproex, initiate felbamate at 1200 mg/day in divided doses 3-4 times daily and reduce divalproex dose by 20%. Monitor for increased valproate concentrations/effects and decreased felbamate concentrations/effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Felbamate may increase the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Felbamate.  Management: Decreased phenytoin dose will likely be needed when adding felbamate; some reports suggest an empiric 20% decrease in phenytoin dose. Additional reductions may be needed if felbamate dose is increased or as otherwise guided by monitoring.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Felbamate may increase the serum concentration of PHENobarbital. PHENobarbital may decrease the serum concentration of Felbamate.  Management: In patients receiving phenobarbital, initiate felbamate at 1200 mg/day in divided doses 3-4 times daily and reduce phenobarbital dose by 20%. Monitor for increased phenobarbital concentrations/effects and decreased felbamate concentrations/effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Felbamate may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Felbamate.  Management: Decreased phenytoin dose will likely be needed when adding felbamate; some reports suggest an empiric 20% decrease in phenytoin dose. Additional reductions may be needed if felbamate dose is increased or as otherwise guided by monitoring.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Felbamate may increase serum concentrations of the active metabolite(s) of Primidone. Specifically, phenobarbital concentrations may increase. Primidone may decrease the serum concentration of Felbamate.  Management: In patients receiving primidone, initiate felbamate at 1200 mg/day in divided doses 3-4 times daily and reduce primidone dose by 20%. Monitor for increased phenobarbital concentrations/effects and decreased felbamate concentrations/effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Felbamate may increase the serum concentration of Valproic Acid.  Management: In patients receiving valproic acid, initiate felbamate at 1200 mg/day in divided doses 3-4 times daily and reduce valproic acid dose by 20%. Monitor for increased valproate concentrations/effects and decreased felbamate concentrations/effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F170118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Tablet: Food does not affect absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid evening primrose (seizure threshold decreased).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F170093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5940223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Postmarketing case reports in humans include fetal death, genital malformation, anencephaly, encephalocele, and placental disorder.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients exposed to felbamate during pregnancy are encouraged to enroll themselves into the North American Antiepileptic Drug (AED)  Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F170131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5940225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Felbamate has been detected in human milk.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F170109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F170108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Felbamate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg/5 mL (240 mL): $641.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Felbatol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg/5 mL (237 mL): $826.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Felbamate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (30): $156.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (90): $538.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Felbatol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (100): $672.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (100): $770.41",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F170095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor serum levels of concomitant anticonvulsant therapy; obtain transaminases (AST, ALT) levels before initiation of therapy and periodically thereafter. Hematologic evaluations before therapy begins, frequently during therapy, and for a significant period after discontinuation. Monitor for suicidality (eg, suicidal thoughts, depression, behavioral changes).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Felbamyl (AR);",
"     </li>",
"     <li>",
"      Taloxa (AT, BE, CH, CZ, DE, ES, FR, HN, HU, IT, LU, NL, NO, PL, PT, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F170085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mechanism of action is unknown but has properties in common with other marketed anticonvulsants; has weak inhibitory effects on GABA-receptor binding, benzodiazepine receptor binding, and is devoid of activity at the MK-801 receptor binding site of the NMDA receptor-ionophore complex.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F170105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and almost complete; food has no effect upon the tablet's absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.7-0.8 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 22% to 25%, primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 20-23 hours (average); prolonged by 9-15 hours in renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (40% to 50% as unchanged drug, 40% as inactive metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      French J, Smith M, Faught E, et al, &ldquo;Practice Advisory: The Use of Felbamate in the Treatment of Patients With Intractable Epilepsy: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1999, 40(6):803-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaufmann DW, Kelly JP, Anderson T, et al, &ldquo;Evaluation of Case Reports of Aplastic Anemia Among Patients Treated With Felbamate,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1997, 38(12):1265-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/31/25079/abstract-text/9578520/pubmed\" id=\"9578520\" target=\"_blank\">",
"        9578520",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pellock JM, &ldquo;Felbamate in Epilepsy Therapy: Evaluating the Risks,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1999, 21(3):225-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/31/25079/abstract-text/10487399/pubmed\" id=\"10487399\" target=\"_blank\">",
"        10487399",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perucca E, &ldquo;Clinically Relevant Drug Interaction With Antiepileptic Drugs,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2005, 61(3):246-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/31/25079/abstract-text/16487217/pubmed\" id=\"16487217\" target=\"_blank\">",
"        16487217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8934 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-210.101.131.231-4F3FA9F29D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_31_25079=[""].join("\n");
var outline_f24_31_25079=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708778\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170122\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170155\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170125\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170142\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170126\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170127\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14456066\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170098\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170082\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11233759\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13114473\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170103\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170102\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170153\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170106\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170086\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170150\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170091\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170118\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170093\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5940223\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170131\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5940225\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170109\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170108\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170095\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038616\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170085\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170105\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8934\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8934|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/1/12310?source=related_link\">",
"      Felbamate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/25/28055?source=related_link\">",
"      Felbamate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_31_25080="Membranous and infundibular VSDs";
var content_f24_31_25080=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F86958%7ECARD%2F72186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F86958%7ECARD%2F72186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Parasternal echocardiographic views of a membranous ventricular septal defect and an infundibular ventricular septal defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Parasternal short axis echocardiographic view with color flow Doppler demonstrating a membranous ventricular septal defect with a left-to-right shunt in proximity to the tricuspid valve (TV) (turbulent flow from LV to RV).",
"    <br/>",
"    (B) Color flow Doppler demonstrating infundibular ventricular septal defect in the right ventricular outflow tract in proximity to the pulmonary valve (PV).",
"    <div class=\"footnotes\">",
"     AO: aorta; LA: left atrium; PA: pulmonary artery; RA: right atrium; RV: right ventricle.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission: Ammash N. Ventricular Septal Defects. In: Adult Congenital Heart Disease, Warnes CA (Ed). &copy; 2009 American Heart Association, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Echocardiogram of infundibular VSD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 383px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transthoracic echocardiogram showing an infundibular or supracristal defect with and without color flow Doppler in systole and diastole. Aortic valve prolapse is seen in early systole (A). As blood is ejected blood from the left ventricle, the anatomically unsupported coronary cusp and aortic sinus are driven into the right ventricle (RV) by a Venturi effect. Color flow Doppler shows left to right shunt across the VSD (B). In diastole (C), the unsupported cusp does not coapt with the other coronary cusps, resulting in aortic regurgitation (AR).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Ammash N. Ventricular Septal Defects. In: Adult Congenital Heart Disease, Warnes, CA (Ed). &copy; 2009 American Heart Association, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_31_25080=[""].join("\n");
var outline_f24_31_25080=null;
var title_f24_31_25081="Bites of widow spiders";
var content_f24_31_25081=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bites of widow spiders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/31/25081/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/31/25081/contributors\">",
"     Richard S Vetter, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/31/25081/contributors\">",
"     David L Swanson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/31/25081/contributors\">",
"     Julian White, MB, BS, MD, FACTM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/31/25081/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/31/25081/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/31/25081/contributors\">",
"     Daniel F Danzl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/31/25081/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/31/25081/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/31/25081/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic will review the arachnology of widow spiders (genus Latrodectus) and the clinical manifestations, diagnosis, differential diagnosis, and management of their bites. An overview of spider bites and the management of bites of other spiders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/16/24839?source=see_link\">",
"     \"Approach to the patient with a suspected spider bite: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24248?source=see_link\">",
"     \"Bites of recluse spiders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ARACHNOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both widow spiders and false widow spiders are of medical importance, although the bites of widow spiders are generally of greater concern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Widow spiders (Genus Latrodectus)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Widow spiders belong to the family Theridiidae, genus Latrodectus. Latrodectism is the term for the medical manifestations of bites by widow spiders [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/16/24839?source=see_link\">",
"     \"Approach to the patient with a suspected spider bite: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are approximately 30 species of widow spiders found worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/3\">",
"     3",
"    </a>",
"    ]. Not all have been implicated in human bites, although this may be partly due to the remote distribution of the spiders away from human populations. Female widow spiders are responsible for most significant bites. Males have less venom, smaller fangs, and weaker biting muscles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Spider identification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most adult widow spiders are shiny black with red markings on the body, although this is not universal. The most common species of medical importance are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American species has a red hourglass or anvil-shaped mark on the ventral portion of the abdomen, which can range from a perfect hourglass to two separated triangles, to one triangle and a barely perceptible lower red mark (",
"      <a class=\"graphic graphic_picture graphicRef78920 \" href=\"UTD.htm?41/54/42853\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef57539 \" href=\"UTD.htm?19/11/19632\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The southern black widow has a red dot just dorsal to the anal region (",
"      <a class=\"graphic graphic_picture graphicRef82471 \" href=\"UTD.htm?3/44/3777\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The Mediterranean species has a smattering of 13 red dots on the dorsum of the abdomen, but lacks ventral red markings.",
"     </li>",
"     <li>",
"      The Australian redback is notable for a conspicuous dorsal red stripe running from the anal region forward to about halfway the distance of the abdomen (",
"      <a class=\"graphic graphic_picture graphicRef54343 \" href=\"UTD.htm?13/58/14246\">",
"       picture 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef62993 \" href=\"UTD.htm?24/60/25538\">",
"       picture 5",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other widow species may not be black. The brown widow has an orange hourglass and a series of white stripes on a tan abdomen, giving it a mottled appearance. Other species in the eastern hemisphere are nearly white.",
"   </p>",
"   <p>",
"    In addition to color variations among species, immature widow spiders often look very different from the adults (",
"    <a class=\"graphic graphic_picture graphicRef65792 \" href=\"UTD.htm?23/55/24438\">",
"     picture 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Worldwide distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Widow spiders are found in warm climates worldwide, but can exist in colder climates with routine winter snows, such as Colorado and in Canada (",
"    <a class=\"graphic graphic_table graphicRef59049 \" href=\"UTD.htm?43/20/44365\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the United States (US), two species are most commonly implicated in envenomations: the southern black widow spider, L. mactans, and the western black widow spider, L. hesperus (",
"      <a class=\"graphic graphic_picture graphicRef61008 \" href=\"UTD.htm?18/31/18930\">",
"       picture 7",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      The western black widow spider is very abundant throughout the southwestern United States where it is not uncommon to collect 60 or more an hour in supportive habitats. This species seems more tolerant of cold temperatures than eastern relatives as it is a common species in urban Colorado and in the dry interior region of Washington State.",
"     </li>",
"     <li>",
"      There are three other widow species in the US, which are of less concern: L. variolus in the northern Midwest, the red-legged widow L. bishopi, in palmetto habitats of Florida, and brown widows.",
"      <br/>",
"      <br/>",
"      The brown widow, L. geometricus, is found in Florida and more recently, in the deep South from Texas to South Carolina and in coastal southern California [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/4\">",
"       4",
"      </a>",
"      ]. Brown widow spiders are also found in many other parts of the world. Their bite is usually mild with pain upon fang penetration and slight erythema at the bite site [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. Rarely, severe pain, nausea, vomiting, hypertension, and fasciculations can occur [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/7-9\">",
"       7-9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The redback spider, L. hasselti, is found throughout Australia, except in the hottest deserts and coldest mountains and is the only widow species on that continent (",
"      <a class=\"graphic graphic_picture graphicRef54343 \" href=\"UTD.htm?13/58/14246\">",
"       picture 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef62993 \" href=\"UTD.htm?24/60/25538\">",
"       picture 5",
"      </a>",
"      ). It also has become established in Japan in the Osaka Prefecture and has been reported in Europe and Dubai [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/10\">",
"       10",
"      </a>",
"      ]. In New Zealand, L. katipo is typically only found very close (&lt;1 km) to the coast in native habitat and is also being supplanted by a South African spider and colonies of the Australian redback spider [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In South America, L. curacaviensis is widespread and L. geometricus has also caused significant bites [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the circum-Mediterranean region, L. tredecimguttatus is the most common biting widow spider. Because the Mediterranean species is found in many countries, it is known by a colorful array of common names, some of which translate into \"black hag\" (Yugoslavia) and \"black wolf\" (Russia) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Habitat",
"    </span>",
"    &nbsp;&mdash;&nbsp;Widow spiders typically live outdoors in the clutter surrounding homes and garages, in woodpiles, in rarely used garden equipment, in pots, and in tools. It is rare to find a widow spider indoors unless there is significant insect traffic inside a structure.",
"   </p>",
"   <p>",
"    Before indoor plumbing, many American and Australian bites by widow spiders occurred in outhouses. Victims were often men, and bites often occurred predominantly on the penis, scrotum, or buttocks [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. This has become such common-place knowledge that it was enshrined in song in Australia (\"There's a redback on the toilet seat\"). In Europe, widow bites were considered an occupational hazard of wheat farmers who compressed the spider against their bodies as they harvested the crop and by other out-of-doors workers, including farm laborers and greenhouse keepers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/2,5\">",
"     2,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, with the advent of indoor plumbing, there was a shift in bite location from the central genitalia to the peripheral limbs. Bites now typically occur as people place their hands into gardening gloves or feet into boots, or compress spiders under potted plants, patio furniture, toys, etc.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     False black widow spiders (Genus Steatoda)",
"    </span>",
"    &nbsp;&mdash;&nbsp;False black widow spiders are found around the world and have a bite that causes mild symptoms of latrodectism, sometimes called steatodism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Appearance and identification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Steatoda spiders are in the same family (Theridiidae) as the black widows and hence, share a similar body form which may cause confusion in identification (",
"    <a class=\"graphic graphic_picture graphicRef51082 \" href=\"UTD.htm?2/25/2455\">",
"     picture 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef73853 \" href=\"UTD.htm?18/25/18834\">",
"     picture 9",
"    </a>",
"    ). They are typically chocolate brown to black in color and may have some tan stripes or markings on the abdomen. Unlike black widows, they do not have red markings on their bodies.",
"   </p>",
"   <p>",
"    There are many species in the genus Steatoda. Most are too small to inflict a medically-important bite due to small fang size, low-venom gland content, or inability of musculature to cause fang penetration in human skin, or a combination of these traits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Worldwide distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;False black widows are found in Europe, the US, and Australia (",
"    <a class=\"graphic graphic_table graphicRef59049 \" href=\"UTD.htm?43/20/44365\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In North America, the false black widow is found commonly along the Pacific Coast from southern California through Washington State into British Columbia. It is also found in Colorado. Steatoda grossa (",
"      <a class=\"graphic graphic_picture graphicRef51082 \" href=\"UTD.htm?2/25/2455\">",
"       picture 8",
"      </a>",
"      ) is the largest of this genus and is the most frequent culprit in bites.",
"     </li>",
"     <li>",
"      In Europe, S. paykulliana is the most medical important species, although S. grossa also exists [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In Australia, S. grossa is the medically important species, widely distributed in urban environments.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Habitat",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like black widow spiders, false black widows are found in trash and clutter. In contrast to black widows, however, they are much more likely to be found inside homes. They do not appear to have the same high-food requirement as black widows and can thus survive indoors where insect traffic is greatly diminished. Steatoda spiders prefer places that are not disturbed and are often found under and within cupboards.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS OF BITES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Black widow spiders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Latrodectism is the medical term for the manifestations (both local and systemic) of bites by widow spiders [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/1,2,12\">",
"     1,2,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Clinical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients presenting with widow bites typically have a recent (&lt;8 hours) history of an at-risk activity, such as gardening, chopping wood, using outdoor furniture, or cleaning out a garage. Approximately 75 percent of bites are on the extremities, particularly the lower extremities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Lesion and local symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical black widow bite is a mild lesion consisting of a blanched circular patch with a surrounding red perimeter and a central punctum (",
"    <a class=\"graphic graphic_picture graphicRef52977 \" href=\"UTD.htm?13/31/13813\">",
"     picture 10",
"    </a>",
"    ). Some bites resemble a wheal and flare reaction. Most bites are either asymptomatic or cause local pain at the site of the bite [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/13\">",
"     13",
"    </a>",
"    ]. The time of onset of more generalized symptoms is typically 40 minutes (20 to 120 minutes range) from the time of the bite, but may be longer on occasion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Significant envenomation causes acute muscle pain and often localized diaphoresis in the affected limb, and this presentation is highly suggestive of a widow bite. If the bite is on the lower extremities, the muscular pain may extend to the abdomen; upper extremity pain may extend to the chest. The pain may be accompanied by tremor, weakness, myoclonus, and local paresthesias. Diaphoresis may extend to involve the whole extremity, the body, or may be limited to areas distant from the bite. There may also be local lymphadenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/15\">",
"     15",
"    </a>",
"    ]. Black widow bites do not become necrotic and secondary infection appears to be rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Systemic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vital signs are usually normal with moderate envenomation, although patients may be anxious and tachypneic. With more extensive envenomation, patients may experience some or all of the following systemic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Generalized musculoskeletal, abdominal, or back pain",
"     </li>",
"     <li>",
"      Hypertension and tachycardia",
"     </li>",
"     <li>",
"      Nausea",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vomiting",
"     </li>",
"     <li>",
"      Generalized or regional diaphoresis",
"     </li>",
"     <li>",
"      Headache",
"     </li>",
"     <li>",
"      Facial swelling, which can be mistaken for an allergic reaction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pain is usually the most prominent feature in systemic reactions. Severe abdominal pain with abdominal wall rigidity, but normal bowel sounds is characteristic. Abdominal pain from a widow bite has been mistaken for a variety of abdominal emergencies, including acute cholecystitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Rarely, intestinal ileus, priapism, cardiomyopathy, pulmonary edema, and cardiovascular collapse may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. Additional reported complications include hematuria, Horner's syndrome, compartment syndrome, rhabdomyolysis, and toxic epidermal necrolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. Death is unusual, even in children, who are generally more affected by envenomations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/25\">",
"     25",
"    </a>",
"    ]. The few cases of latrodectism with documented rhabdomyolysis do not show a large rise in serum creatine phosphokinase.",
"   </p>",
"   <p>",
"    Patients presenting late with latrodectism, irrespective of the bite location, often manifest burning pain in the soles of the feet, pain in the legs, below the knee, and profuse sweating below knees.",
"   </p>",
"   <p>",
"    In infants, latrodectism may present as a distressed and inconsolable child who is refusing food and drink and has generalized erythema. A classic story would be of a newborn who develops the above clinical findings after being brought home and placed in a cot that had been stored in a garage. In such cases, a squashed widow spider may be found on searching the area in which the infant was lying or sleeping.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Venom properties",
"    </span>",
"    &nbsp;&mdash;&nbsp;Black widow venom contains neurotoxins of the latrotoxin type, including a vertebrate-specific toxin called alpha-latrotoxin, a large protein toxin (120 kDa) that triggers massive exocytosis from presynaptic nerve terminals and in a variety of neurosecretory cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/26\">",
"     26",
"    </a>",
"    ]. Acetylcholine, norepinephrine, dopamine, glutamate, and enkephalin systems are all susceptible to the toxin [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/6,26-30\">",
"     6,26-30",
"    </a>",
"    ]. It appears this toxin is present in the venom of all medically important widow spiders and this has clear implications for cross reactivity of anti-Latrodectus antivenoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Laboratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory findings are non-specific and not necessary to make the diagnosis of latrodectism. Abnormal laboratory studies at presentation most frequently include elevations in white blood cell counts and serum concentrations of creatine phosphokinase, glucose,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    liver enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     False black widow spider",
"    </span>",
"    &nbsp;&mdash;&nbsp;Steatoda bites cause symptoms that are similar, but less severe than black widow bites, as the venoms have similar properties.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Clinical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The false black widow is found in trash and clutter, and is much more likely to be found inside homes. In an Australian series that included 23 verified Steatoda bites, 78 percent of bites occurred indoors, often while dressing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/31\">",
"     31",
"    </a>",
"    ]. Bites occurred throughout the year and mostly during waking hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all bites are painful, and pain may increase during the first hour [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/5,31\">",
"     5,31",
"    </a>",
"    ]. In the Australian series, median duration of pain was six hours, and one-third of victims seeking medical attention had systemic symptoms, including nausea, headache, lethargy, and malaise [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/31\">",
"     31",
"    </a>",
"    ]. There was no associated diaphoresis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A presumptive diagnosis of a spider bite is most often based on the history and clinical presentation. Of note, the diagnosis of a spider bite can be considered definitive only if both of the following criteria are fulfilled:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A spider was observed inflicting the bite.",
"     </li>",
"     <li>",
"      The spider was recovered, collected, and properly identified by an expert",
"      <span class=\"nowrap\">",
"       arachnologist/entomologist.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If both of the above conditions are not met, then other conditions, such as vasculitis, infection, vascular problems, or other relevant disorders must be considered and where appropriate, excluded. However, latrodectism has a number of distinctive features. In regions where widow spiders are common, it is acceptable for clinicians to make a diagnosis of latrodectism without formal sighting of a confirmed widow spider.",
"   </p>",
"   <p>",
"    The general approach to a patient suspected of having a spider bite, as well as the differential diagnosis of a non-necrotic spider bite, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/16/24839?source=see_link\">",
"     \"Approach to the patient with a suspected spider bite: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The painful muscle spasms of latrodectism may mimic a variety of other painful conditions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Surgical abdomen",
"      </strong>",
"      &ndash; Abdominal muscle spasms and pain may be mistaken for a surgical abdomen, as mentioned previously [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/16\">",
"       16",
"      </a>",
"      ]. Other signs and symptoms may help distinguish latrodectism from other entities. For example, patients with a surgical abdomen (eg, appendicitis) tend to be tired, have constant pain, and are often hypotensive when peritonitis is present. Patients with latrodectism are more likely to be hypertensive, hyperactive, and have intermittent muscle spasms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=see_link\">",
"       \"Diagnostic approach to abdominal pain in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22490?source=see_link\">",
"       \"Emergent evaluation of the child with acute abdominal pain\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Myocardial",
"       <span class=\"nowrap\">",
"        ischaemia/infarction",
"       </span>",
"      </strong>",
"      &ndash; The severe pain of systemic latrodectism can cause severe chest pain, with hypertension, sweating and nausea that can simulate myocardial ischemia or infarction. Serial ECG and cardiac biomarkers adequately differentiate the etiology of chest pain.",
"     </li>",
"     <li>",
"      <strong>",
"       Rabies",
"      </strong>",
"      &ndash; Latrodectism may also be confused with rabies. Patients with rabies present with excessive motor activity, excitation, and agitation with seizures and a characteristic \"fear of water\" (hydrophobia) due to a painful, violent, involuntary contraction of pharyngeal and laryngeal muscles. In most cases of rabies, patients can report a definite bite or at least direct contact with an animal. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29624?source=see_link\">",
"       \"Clinical manifestations and diagnosis of rabies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Tetanus",
"      </strong>",
"      &ndash; Tetanus may mimic the muscle spasm associated with systemic latrodectism. Tetanus causes increased muscle tone and generalized spasms, particularly of the central muscles, and increased tone in the masseter muscle (trismus). Patients may have autonomic overactivity, presenting as irritability, restlessness, sweating, and tachycardia. In later phases of illness, profuse sweating, cardiac arrhythmias, labile hypertension or hypotension, and fever are often present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7353?source=see_link\">",
"       \"Tetanus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients who sustain a widow spider bite require only local care of the lesion. Patients with moderate to severe envenomations, characterized by severe local symptoms or the presence of regional or systemic symptoms, may require supportive care and monitoring for complications. Antivenoms are also available for treatment of widow spider bites in selected cases. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Widow antivenoms'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The current recommendations for treatment of widow bites are primarily based on case reports and retrospective series [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/12\">",
"     12",
"    </a>",
"    ]. Small randomized controlled trials of redback spider antivenom have been performed in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Efficacy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     General measures following bites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment measures following a spider bite include [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clean the bite with mild soap and water.",
"     </li>",
"     <li>",
"      Administer pain medication, as needed. Most cases will respond to oral analgesia.",
"     </li>",
"     <li>",
"      Provide parenteral benzodiazepines (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      ) to patients with severe muscle spasm.",
"     </li>",
"     <li>",
"      Administer tetanus prophylaxis, if indicated (",
"      <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Local application of cold packs and elevation of the affected body part have also been suggested. However, local swelling is usually minimal, and these treatments do not have any other known benefit for widow spider envenomation. Thus, we do not routinely recommend them.",
"   </p>",
"   <p>",
"    Most bites can be managed with minimal intervention and heal without scarring. Resolving bites should be monitored for the development of secondary bacterial infection, although this is a rare complication.",
"   </p>",
"   <p>",
"    Intravenous calcium does not appear to be effective for the treatment of pain after a widow spider bite based on an observational study of 163 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/13\">",
"     13",
"    </a>",
"    ]. In this series, 23 of 24 (96 percent) moderately or severely envenomated patients had no relief after intravenous calcium therapy and required other treatment (parenteral opioids and benzodiazepines or antivenom).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Indications for antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics are prescribed only if there are signs of infection, such as increased erythema, fluctuation, and suppuration. The treatment of infected bites requires antibiotics directed against skin pathogens, as indicated in the table (",
"    <a class=\"graphic graphic_table graphicRef64128 \" href=\"UTD.htm?23/12/23756\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link\">",
"     \"Cellulitis and erysipelas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Widow antivenoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mortality associated with widow bites is low, although envenomation can cause significant pain and require hospitalization. Antivenom reduces the pain associated with bites (and may have a more prolonged effect than analgesics) and reduces the need for hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/13,35\">",
"     13,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several widow spider antivenoms are commercially available, including the American black widow spider (L. mactans) antivenom and the Australian redback spider (L. hasselti) antivenom [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/36\">",
"     36",
"    </a>",
"    ]. There is sufficient chemical similarity among widow venoms that all widow antivenoms provide some degree of relief following bites of various widow spiders. As an example, case reports describe successful use of redback antivenom in treating the bites of both the false black widow and the American southern black widow [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, it has been recommended that widow antivenom not be stockpiled [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/39\">",
"     39",
"    </a>",
"    ]. Instead, clinicians can order it through hospital pharmacies by express delivery. In areas of the world in which redback spiders are prevalent, it is a routinely-stocked antivenom. Currently, in Australia, more redback spider antivenom is used than all other antivenoms, including snake antivenoms, combined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consultation with a medical toxicologist, clinical toxinologist or other physician with experience in managing widow spider bites is recommended prior to antivenom administration. Phone consultation with a medical toxicologist is available through a United States regional poison control center by calling 1-800-222-1222. In Australia, expert advice can be obtained through the poisons information system by calling 13 11 26, or through the clinical toxinology service in Adelaide by calling 08-81617000. For clinicians outside of the United States and Australia, the World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    We suggest that widow antivenoms be administered for moderate to severe symptoms of latrodectism that are unresponsive to other therapies. Representative symptoms include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe and persistent local pain or muscle cramping",
"     </li>",
"     <li>",
"      Significant pain or diaphoresis extending beyond the immediate site of the bite",
"     </li>",
"     <li>",
"      Alterations in vital signs",
"     </li>",
"     <li>",
"      Difficulty breathing",
"     </li>",
"     <li>",
"      Nausea and vomiting",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Widow antivenom has been given in pregnancy with no adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a clear difference in approach to treatment of latrodectism in different parts of the world. In North America, due to concerns about Latrodectus mactans antivenom safety [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/13\">",
"     13",
"    </a>",
"    ], antivenom is primarily used in severe to life-threatening envenomation, which will result in patients with moderate regional or systemic symptoms suffering for a period of several days.",
"   </p>",
"   <p>",
"    In Australia, the antivenom is used as first line treatment for almost all cases of latrodectism that do not fully respond to a trial of oral analgesia. Observational data indicate approximately 1000 patients receive this antivenom each year [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/41\">",
"     41",
"    </a>",
"    ]. There are no confirmed fatalities from adverse reactions to the antivenom, suggesting that this antivenom is safe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;American",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/12/31941?source=see_link\">",
"     black widow spider (Latrodectus mactans) antivenom",
"    </a>",
"    significantly reduced the duration of all symptoms in one series of 58 treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/13\">",
"     13",
"    </a>",
"    ]. Complete resolution of symptoms occurred in a mean time of 31 &plusmn; 27 minutes after antivenom administration. The mean total duration of symptoms was 9 &plusmn; 23 hours in patients receiving antivenom, compared with 22 &plusmn; 25 hours in patients not receiving this intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/13\">",
"     13",
"    </a>",
"    ]. Admission rates were 12 and 52 percent in those receiving antivenom and controls, respectively. Another case series reported similar outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Australian redback spider antivenom has been given intramuscularly (IM) and intravenously (IV). One large observational study found that IM redback antivenom had effectiveness for reducing pain symptoms as high as 94 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/42\">",
"     42",
"    </a>",
"    ]. The intravenous route may also be effective in patients who have not responded fully to intramuscular injection and appears safe [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. The intravenous route has traditionally been preferred for patients with severe systemic symptoms and for children younger than 12 years. Clinical experience and animal studies have suggested that intravenous use may be more efficacious [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Available evidence indicates IM absorption of antivenom, as measured by intravascular levels, is slow. There is also a small, but growing body of evidence questioning the efficacy of IM redback spider antivenom in Australia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/32,33,43\">",
"     32,33,43",
"    </a>",
"    ], despite earlier studies suggesting it was efficacious [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/42,45,46\">",
"     42,45,46",
"    </a>",
"    ], and there is a discernible shift in use amongst emergency physicians towards IV administration [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/47\">",
"     47",
"    </a>",
"    ]. The relative efficacy of IV or IM Australian redback spider antivenom administration has been examined in small randomized trials with varying results [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter trial of 31 patients found that Australian redback spider antivenom provided rapid pain relief when given IV or IM. However, patients who received IV antivenom were much more likely to be pain free at 24 hours than those treated IM (76 versus 21 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A multicenter trial of 126 patients demonstrated slightly increased pain reduction 2 hours and 24 hours after IV Australian redback spider antivenom treatment (62 percent for IV versus 53 percent for IM at 2 hours, 84 percent for IV and 71 percent for IM at 24 hours) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/34\">",
"       34",
"      </a>",
"      ]. Approximately 20 percent of patients in both groups required opioid analgesia after emergency department discharge and were unable to sleep in the first 24 hours because of pain. Acute hypersensitivity reactions were reported in 5 percent of patients in both groups. Serum sickness was more frequent in patients receiving IM antivenom (16 percent IM versus 11 percent IV). The high number of patients with persistent pain at 24 hours and the frequency of adverse reactions caused the investigators to question the effectiveness of Australian redback spider antivenom regardless of route of administration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the benefit described in large observational studies of antivenom administration for Australian redback spider bites [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/42\">",
"     42",
"    </a>",
"    ], we suggest that this antivenom is effective for relieving pain in selected patients. However, trials that directly evaluate antivenom therapy versus supportive care alone are indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Precautions concerning allergic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concerns about potential allergic reactions have influenced the approach to treatment with widow antivenoms in different countries.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 58 patients published in 1992, administration of American black widow antivenom (containing whole horse IgG) resulted in five allergic reactions (9 percent), of which four were mild and one was fatal [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/13\">",
"       13",
"      </a>",
"      ]. The patient who died had asthma and multiple drug allergies, and was given undiluted antivenom as a rapid intravenous push [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/48\">",
"       48",
"      </a>",
"      ]. Following this report, the use of black widow antivenom declined in the United States. In 2011, an additional case report described anaphylaxis and death after administration of dilute antivenom to a 37 year old man with asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an Australian series, redback antivenom (composed of horse F[ab]2 fragments) caused 11 immediate anaphylactic reactions in approximately 2000 administrations (0.54 percent), and there were no fatalities [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/15\">",
"       15",
"      </a>",
"      ]. A retrospective review of antivenom use in Australia over a two-year period reported that redback spider antivenom was administered in about 20 percent of cases that presented for medical care [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, it is not clear from the limited literature available that there are significant differences in the risk of allergic reactions to different antivenoms using current methods of administration, although clinicians must weigh the risks and benefits of antivenoms in each case. The risk of an allergic reaction should be discussed with the patient or guardian prior to administration whenever possible and asthma considered a possible contraindication.",
"   </p>",
"   <p>",
"    It is important for the",
"    <span class=\"nowrap\">",
"     patient/guardian",
"    </span>",
"    to understand that latrodectism is unlikely to be a fatal disease process. Thus, antivenom is not life-saving. However, without antivenom, the patient will likely have a prolonged period of distressing symptoms and that of all available treatments, current evidence indicates antivenom is the most likely to be effective and may significantly reduce the duration of suffering and hospitalization.",
"   </p>",
"   <p>",
"    Prior to the administrations of widow antivenom, medications and equipment for the treatment of anaphylaxis should be immediately available, including IV fluids, epinephrine, and intubation equipment. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Dosing and administration'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Allergic reactions should be managed by immediately stopping intravenous infusion of the antivenom (if applicable) and treating symptoms appropriately (",
"    <a class=\"graphic graphic_table graphicRef58346 \" href=\"UTD.htm?16/26/16813\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74242 \" href=\"UTD.htm?17/50/18221\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delayed serum sickness-like reactions are reported in 1 to 2 percent of patients receiving widow antivenoms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/15,50\">",
"     15,50",
"    </a>",
"    ]. All patients receiving antivenom should be informed of the possibility of serum sickness, the symptoms suggestive of serum sickness and advised to seek medical care if such symptoms occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8842?source=see_link\">",
"     \"Serum sickness and serum sickness-like reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Dosing and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Widow antivenoms should be given as soon as possible after the onset of significant symptoms warranting antivenom therapy, although patients with ongoing symptoms may benefit from treatment even days after the bite [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Indications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Consultation with a medical toxicologist, clinical toxinologist, or other physician with expertise and prior experience treating spider bites is strongly recommended before initiating antivenom therapy. For emergency consultation with a medical toxicologist, the clinician may call 1-800-222-1222 in the USA. In Australia, expert advice can be obtained through the poisons information system by calling 13 11 26, or through the clinical toxinology service in Adelaide by calling 08-81617000. Outside of the USA and Australia, the World Health Organization provides a listing of international poison centers at its website: (",
"      <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"       www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Antivenom administration has a significant risk of allergic complications and should only occur in a continuously monitored emergency or intensive care unit setting. Airway equipment, epinephrine, antihistamine medication, and isotonic IV fluids should be available for immediate treatment of anaphylaxis (",
"      <a class=\"graphic graphic_table graphicRef58346 \" href=\"UTD.htm?16/26/16813\">",
"       table 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef74242 \" href=\"UTD.htm?17/50/18221\">",
"       table 5",
"      </a>",
"      ). There is no place for pre-administration sensitivity testing of spider antivenoms; this procedure is non-predictive and hazardous and should not be performed. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Precautions concerning allergic reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Premedication prior to antivenom use is controversial, with most evidence indicating it is either of doubtful efficacy or without merit [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/41\">",
"       41",
"      </a>",
"      ]. Although a trial of several premedication regimens prior to Indian snake antivenom administration, found a marked decrease in severe reactions for patients who received epinephrine [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/55\">",
"       55",
"      </a>",
"      ], this snake antivenom has a much higher rate of adverse reactions when compared to widow spider antivenoms (75 versus 11 percent, respectively). Thus, unless there are clear, patient specific reasons for providing premedication (eg, known prior allergic reaction to widow spider antivenom), we do not advise it for patients receiving widow spider antivenoms.",
"      <br/>",
"      <br/>",
"      Widow spider antivenoms may be administered intravenously or intramuscularly (eg, in the lateral thigh). The initial dose of antivenom will vary depending on the product used. Clinicians should be guided by a poison control center, medical toxicologist, clinical toxinologist,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      information provided by the manufacturer. As with all other antivenoms, if used intravenously, secure IV access must first be established, the antivenom should be diluted, and then given either by slow \"push\" or continuous infusion, with the clinician present throughout administration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/12/31941?source=see_link\">",
"       Black widow spider antivenom",
"      </a>",
"      &ndash; The initial dose of black widow spider antivenom (Antivenin Latrodectus mactans equine) is 6000 antivenom units (equal to the entire contents of one reconstituted vial). The black widow (Latrodectus mactans) antivenom available in the United States is freeze dried and should be reconstituted in the 2.5 mL sterile diluent that is supplied. For intravenous administration in adults and children, we suggest further diluting the solution by adding it to 250 mL of normal saline. We administer this initially at 1 mL per minute for 15 minutes, with careful observation for signs of an allergic reaction (flushing, hives, itching, bronchospasm, etc). If this initial administration is tolerated, we complete the infusion over one hour [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/48,56\">",
"       48,56",
"      </a>",
"      ]. If there is no improvement, a second and third vial can be given at hourly intervals.",
"     </li>",
"     <li>",
"      <strong>",
"       Redback spider antivenom",
"      </strong>",
"      &ndash; The redback spider antivenom that is available in Australia comes in vials containing 500 units of antivenom in 1 to 1.5 mL solutions. Two vials are usually administered either undiluted, by intramuscular injection into the anterolateral thigh, or intravenously after the two vials are diluted into 200 mL of normal saline or 5 percent dextrose [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/57\">",
"       57",
"      </a>",
"      ]. If response is not complete or symptoms begin to return, then a second dose of two vials may be given one hour after the first. A third dose of two vials may be given, although the diagnosis of widow spider bite should be reconsidered if there has been no response by the second or third dose [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In an Australian series, 76 percent of patients required only one vial, while two and three vials were needed in 18 and 6 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/42\">",
"     42",
"    </a>",
"    ]. However, the Australian National Poisons Information Center Network recommends that all cases receive two vial increments [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/57\">",
"     57",
"    </a>",
"    ], as do state health department guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25081/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     DISCHARGE INSTRUCTIONS AND AFTER CARE",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients should be counseled about how to care for the bite site and advised to watch the site for signs of secondary bacterial infection (eg, fever, spreading redness, pus formation, or drainage).",
"     </li>",
"     <li>",
"      Patients who received antivenom should be informed of the symptoms of serum sickness, which may develop within the subsequent two to three weeks. They should seek medical care promptly for suggestive symptoms, including fever, rash, joint pain, and malaise. Serum sickness reactions may require treatment with systemic glucocorticoids. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8842?source=see_link\">",
"       \"Serum sickness and serum sickness-like reactions\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/16/10498?source=see_link\">",
"       \"Patient information: Spider bites (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7811867\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Widow spiders (Genus Latrodectus) are found in warm climates worldwide and are capable of inflicting bites in humans. These spiders vary in appearance, although the American black widow (",
"    <a class=\"graphic graphic_picture graphicRef78920 \" href=\"UTD.htm?41/54/42853\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef57539 \" href=\"UTD.htm?19/11/19632\">",
"     picture 2",
"    </a>",
"    ) and the Australian redback (",
"    <a class=\"graphic graphic_picture graphicRef54343 \" href=\"UTD.htm?13/58/14246\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef62993 \" href=\"UTD.htm?24/60/25538\">",
"     picture 5",
"    </a>",
"    ) are distinctive in appearance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Clinical findings",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients presenting with widow bites typically have a recent (&lt;8 hours) history of some outdoor activity such as gardening, sitting in outdoor furniture, or cleaning out a garage. Approximately 75 percent of bites are on the extremities. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients presenting with possible spider bites should always be questioned carefully regarding the circumstances surrounding the bite. Other disorders are responsible for most skin lesions attributed to spider bites, unless the patient witnessed the spider inflicting the bite and can retrieve the spider for identification by an arachnologist or entomologist. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Lesion and local symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with regional or systemic findings of latrodectism may be diagnosed and treated in the absence of an identified widow spider bite. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/16/24839?source=see_link\">",
"       \"Approach to the patient with a suspected spider bite: An overview\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Latrodectism is the medical term for the manifestations (both local and systemic) of bites of widow spiders. The typical black widow bite is a mild lesion consisting of a blanched circular patch with a surrounding red perimeter and a central punctum. Most bites are either asymptomatic or cause local pain. Significant envenomation causes prominent muscle pain and localized diaphoresis in the affected limb. Pain may spread to the abdomen, chest, or back. With severe envenomations, tachypnea, diaphoresis, hypertension, nausea, and painful muscle spasms may be seen. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical manifestations of bites'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The symptoms of systemic latrodectism can mimic a surgical abdomen, myocardial infarction, rabies, or tetanus. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial treatment measures following a spider bite include local wound care, pain medication, and tetanus prophylaxis (",
"      <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"       table 2",
"      </a>",
"      ). Most bites do not require additional intervention. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with symptoms of moderate to severe envenomation that persist despite the measures above, we suggest the administration of widow antivenom (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Widow antivenoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Allergic reactions are a possibility with antivenoms. Patients should be informed of this, and medications and equipment for the treatment of anaphylaxis should be immediately available, including IV fluids, epinephrine, and intubation equipment. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Precautions concerning allergic reactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     DISCLOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dr. White is the clinical toxinology consultant for CSL, Ltd., the sole producer of spider antivenoms for Australia. In this role, he provides assistance to clinicians managing patients with spider bites, regardless of their need for antivenom.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Maretic, Z, Lebez D. Araneism with special reference to Europe, Polit, Pula, Yugoslavia 1979.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/2\">",
"      Vetter RS, Isbister GK. Medical aspects of spider bites. Annu Rev Entomol 2008; 53:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/3\">",
"      Garb JE, Gonz&aacute;lez A, Gillespie RG. The black widow spider genus Latrodectus (Araneae: Theridiidae): phylogeny, biogeography, and invasion history. Mol Phylogenet Evol 2004; 31:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/4\">",
"      Brown KS, Necaise JS, Goddard J. Additions to the known U.S. distribution of Latrodectus geometricus (Araneae: Theridiidae). J Med Entomol 2008; 45:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/5\">",
"      M&uuml;ller GJ. Black and brown widow spider bites in South Africa. A series of 45 cases. S Afr Med J 1993; 83:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/6\">",
"      Saibil HR. The black widow's versatile venom. Nat Struct Biol 2000; 7:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/7\">",
"      Goddard J, Upshaw S, Held D, Johnnson K. Severe reaction from envenomation by the brown widow spider, Latrodectus geometricus (Araneae: Theridiidae). South Med J 2008; 101:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/8\">",
"      Kiriakos D, N&uacute;&ntilde;ez P, Parababire Y, et al. First case of human latrodectism in Venezuela. Rev Soc Bras Med Trop 2008; 41:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/9\">",
"      Ramialiharisoa A, de Haro L, Jouglard J, Goyffon M. [Latrodectism in Madagascar]. Med Trop (Mars) 1994; 54:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/10\">",
"      Nihei N, Yoshida M, Kaneta H, et al. Analysis on the dispersal pattern of newly introduced Latrodectus hasseltii (Araneae: Theridiadae) in Japan by spider diagram. J Med Entomol 2004; 41:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/11\">",
"      Hann, SW. Evidence for the displacement of an endemic New Zealand spider, Latrodectus katipo Powell by the South African species Steatoda capensis. NZ J Zool 1990; 17:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/12\">",
"      Isbister GK, Fan HW. Spider bite. Lancet 2011; 378:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/13\">",
"      Clark RF, Wethern-Kestner S, Vance MV, Gerkin R. Clinical presentation and treatment of black widow spider envenomation: a review of 163 cases. Ann Emerg Med 1992; 21:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/14\">",
"      D&iacute;ez Garc&iacute;a F, Laynez Bretones F, G&aacute;lvez Contreras MC, et al. [Black widow spider (Latrodectus tredecimguttatus) bite. Presentation of 12 cases]. Med Clin (Barc) 1996; 106:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/15\">",
"      Sutherland SK, Trinca JC. Survey of 2144 cases of red-back spider bites: Australia and New Zealand, 1963--1976. Med J Aust 1978; 2:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/16\">",
"      Bush SP. Black widow spider envenomation mimicking cholecystitis. Am J Emerg Med 1999; 17:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/17\">",
"      La Grange MA. Pulmonary oedema from a widow spider bite. S Afr Med J 1990; 77:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/18\">",
"      Kleiner-Baumgarten A. [Black widow spider bite in the Negev]. Harefuah 1991; 120:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/19\">",
"      Levine M, Canning J, Chase R, Ruha AM. Cardiomyopathy following latrodectus envenomation. West J Emerg Med 2010; 11:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/20\">",
"      Quan D, Ruha AM. Priapism associated with Latrodectus mactans envenomation. Am J Emerg Med 2009; 27:759.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/21\">",
"      Rosenthal G, Marcus M, Bakalash S, Lifshitz T. Late Horner's syndrome following the bite of a black widow spider. Int Ophthalmol 1999; 23:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/22\">",
"      Cohen J, Bush S. Case report: compartment syndrome after a suspected black widow spider bite. Ann Emerg Med 2005; 45:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/23\">",
"      Welch KJ, Burke WA, Jones BE. Black widow spider poisoning as a possible cause of toxic epidermal necrolysis. Int J Dermatol 1991; 30:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/24\">",
"      Press J, Gedalia A. [Spider bite in a child]. Harefuah 1989; 116:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/25\">",
"      Woestman R, Perkin R, Van Stralen D. The black widow: is she deadly to children? Pediatr Emerg Care 1996; 12:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/26\">",
"      S&uuml;dhof TC. alpha-Latrotoxin and its receptors: neurexins and CIRL/latrophilins. Annu Rev Neurosci 2001; 24:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/27\">",
"      Peterson ME. Black widow spider envenomation. Clin Tech Small Anim Pract 2006; 21:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/28\">",
"      Nicholson GM, Graudins A. Spiders of medical importance in the Asia-Pacific: atracotoxin, latrotoxin and related spider neurotoxins. Clin Exp Pharmacol Physiol 2002; 29:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/29\">",
"      Henkel AW, Sankaranarayanan S. Mechanisms of alpha-latrotoxin action. Cell Tissue Res 1999; 296:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/30\">",
"      Orlova EV, Rahman MA, Gowen B, et al. Structure of alpha-latrotoxin oligomers reveals that divalent cation-dependent tetramers form membrane pores. Nat Struct Biol 2000; 7:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/31\">",
"      Isbister GK, Gray MR. Effects of envenoming by comb-footed spiders of the genera Steatoda and Achaearanea (family Theridiidae: Araneae) in Australia. J Toxicol Clin Toxicol 2003; 41:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/32\">",
"      Isbister GK, Gray MR. Latrodectism: a prospective cohort study of bites by formally identified redback spiders. Med J Aust 2003; 179:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/33\">",
"      Ellis RM, Sprivulis PC, Jelinek GA, et al. A double-blind, randomized trial of intravenous versus intramuscular antivenom for red-back spider envenoming. Emerg Med Australas 2005; 17:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/34\">",
"      Isbister GK, Brown SG, Miller M, et al. A randomised controlled trial of intramuscular vs. intravenous antivenom for latrodectism--the RAVE study. QJM 2008; 101:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/35\">",
"      Dzelalija B, Medic A. Latrodectus bites in northern Dalmatia, Croatia: clinical, laboratory, epidemiological, and therapeutical aspects. Croat Med J 2003; 44:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/36\">",
"      Isbister GK, Graudins A, White J, Warrell D. Antivenom treatment in arachnidism. J Toxicol Clin Toxicol 2003; 41:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/37\">",
"      Graudins A, Gunja N, Broady KW, Nicholson GM. Clinical and in vitro evidence for the efficacy of Australian red-back spider (Latrodectus hasselti) antivenom in the treatment of envenomation by a Cupboard spider (Steatoda grossa). Toxicon 2002; 40:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/38\">",
"      Daly FF, Hill RE, Bogdan GM, Dart RC. Neutralization of Latrodectus mactans and L. hesperus venom by redback spider (L. hasseltii) antivenom. J Toxicol Clin Toxicol 2001; 39:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/39\">",
"      Dart RC, Goldfrank LR, Chyka PA, et al. Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States. Ann Emerg Med 2000; 36:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/40\">",
"      Russell FE, Marcus P, Streng JA. Black widow spider envenomation during pregnancy. Report of a case. Toxicon 1979; 17:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/41\">",
"      Soh SY, Rutherford G. Evidence behind the WHO guidelines: hospital care for children: should s/c adrenaline, hydrocortisone or antihistamines be used as premedication for snake antivenom? J Trop Pediatr 2006; 52:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/42\">",
"      White J. Envenoming and antivenom use in Australia. Toxicon 1998; 36:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/43\">",
"      Isbister GK. Failure of intramuscular antivenom in Red-back spider envenoming. Emerg Med (Fremantle) 2002; 14:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/44\">",
"      Isbister GK. Safety of i.v. administration of redback spider antivenom. Intern Med J 2007; 37:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/45\">",
"      WIENER S. Red back spider bite in Australia: an analysis of 167 cases. Med J Aust 1961; 48(2):44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/46\">",
"      Jelinek GA, Banham ND, Dunjey SJ. Red-back spider-bites at Fremantle Hospital, 1982-1987. Med J Aust 1989; 150:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/47\">",
"      Brown SG, Isbister GK, Stokes B. Route of administration of redback spider bite antivenom: determining clinician beliefs to facilitate Bayesian analysis of a clinical trial. Emerg Med Australas 2007; 19:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/48\">",
"      Clark RF. The safety and efficacy of antivenin Latrodectus mactans. J Toxicol Clin Toxicol 2001; 39:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/49\">",
"      Murphy CM, Hong JJ, Beuhler MC. Anaphylaxis with Latrodectus antivenin resulting in cardiac arrest. J Med Toxicol 2011; 7:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/50\">",
"      Sutherland SK. Antivenom use in Australia. Premedication, adverse reactions and the use of venom detection kits. Med J Aust 1992; 157:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/51\">",
"      O'Malley GF, Dart RC, Kuffner EF. Successful treatment of latrodectism with antivenin after 90 hours. N Engl J Med 1999; 340:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/52\">",
"      Suntorntham S, Roberts JR, Nilsen GJ. Dramatic clinical response to the delayed administration of black widow spider antivenin. Ann Emerg Med 1994; 24:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/53\">",
"      White J, Harbord M. Latrodectism as mimic. Med J Aust 1985; 142:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/54\">",
"      Banham ND, Jelinek GA, Finch PM. Late treatment with antivenom in prolonged red-back spider envenomation. Med J Aust 1994; 161:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25081/abstract/55\">",
"      de Silva HA, Pathmeswaran A, Ranasinha CD, et al. Low-dose adrenaline, promethazine, and hydrocortisone in the prevention of acute adverse reactions to antivenom following snakebite: a randomised, double-blind, placebo-controlled trial. PLoS Med 2011; 8:e1000435.",
"     </a>",
"    </li>",
"    <li>",
"     Bush SP, Smith JC. Spider envenomation, widow. www.emedicine.com/emerg/topic546.htm (Accessed on September 30, 2008).",
"    </li>",
"    <li>",
"     White J. Snakebite &amp; Spiderbite: Management Guidelines for South Australia. Dept. of Health, Government of South Australia, 2006. Accessible at: file://www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+health+internet/health+information/health+information+for+the+clinician/snakebite+and+spider.",
"    </li>",
"    <li>",
"     CSL Antivenom Handbook. file://www.toxinology.com/generic_static_files/cslb_index.html (Accessed on October 14, 2008).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6510 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-197.136.42.3-2402AFD0B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_31_25081=[""].join("\n");
var outline_f24_31_25081=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ARACHNOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Widow spiders (Genus Latrodectus)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Spider identification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Worldwide distribution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Habitat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      False black widow spiders (Genus Steatoda)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Appearance and identification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Worldwide distribution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Habitat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL MANIFESTATIONS OF BITES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Black widow spiders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Clinical history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Lesion and local symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Systemic symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Venom properties",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      False black widow spider",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Clinical history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      General measures following bites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Indications for antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Widow antivenoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Precautions concerning allergic reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Dosing and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      DISCHARGE INSTRUCTIONS AND AFTER CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7811867\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Clinical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      DISCLOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6510\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6510|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/54/42853\" title=\"picture 1\">",
"      Black widow spider ventral surface",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/11/19632\" title=\"picture 2\">",
"      Black widow spider 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/44/3777\" title=\"picture 3\">",
"      Southern black widow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/58/14246\" title=\"picture 4\">",
"      Widow spider A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/60/25538\" title=\"picture 5\">",
"      Widow spider B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/55/24438\" title=\"picture 6\">",
"      Widow spiderlings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/31/18930\" title=\"picture 7\">",
"      Western black widow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/25/2455\" title=\"picture 8\">",
"      False black widow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/25/18834\" title=\"picture 9\">",
"      False black widow spider",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/31/13813\" title=\"picture 10\">",
"      Widow bite",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6510|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/20/44365\" title=\"table 1\">",
"      Spider entomology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/52/8013\" title=\"table 2\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/12/23756\" title=\"table 3\">",
"      Empiric antibiotics cellulitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/26/16813\" title=\"table 4\">",
"      Emergent management of anaphylaxis in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/50/18221\" title=\"table 5\">",
"      Rapid overview for pediatric anaphylaxis treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/16/24839?source=related_link\">",
"      Approach to the patient with a suspected spider bite: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24248?source=related_link\">",
"      Bites of recluse spiders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29624?source=related_link\">",
"      Clinical manifestations and diagnosis of rabies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=related_link\">",
"      Diagnostic approach to abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22490?source=related_link\">",
"      Emergent evaluation of the child with acute abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/16/10498?source=related_link\">",
"      Patient information: Spider bites (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8842?source=related_link\">",
"      Serum sickness and serum sickness-like reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7353?source=related_link\">",
"      Tetanus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_31_25082="Sedative-analgesic medications in critically ill patients: Properties, dosage regimens, and adverse effects";
var content_f24_31_25082=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sedative-analgesic medications in critically ill patients: Properties, dosage regimens, and adverse effects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/31/25082/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/31/25082/contributors\">",
"     Karen J Tietze, PharmD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/31/25082/contributors\">",
"     Barry Fuchs, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/31/25082/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/31/25082/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/31/25082/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/31/25082/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/31/25082/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distress generally presents as agitation. It is common among critically ill patients, especially those who are intubated or are having difficulty communicating with their caregivers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/1\">",
"     1",
"    </a>",
"    ]. Distress needs to be treated for patient comfort and because it increases sympathetic tone, which may have untoward physiological effects [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Common sedative-analgesic medications used to treat distress are reviewed here. Identifying the cause of distress and using this information to select the optimal sedative-analgesic agent is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15833?source=see_link\">",
"     \"Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of pain and neuromuscular blockade in critically ill patients are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=see_link\">",
"     \"Pain control in the critically ill adult patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43720?source=see_link\">",
"     \"Use of neuromuscular blocking medications in critically ill patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BENZODIAZEPINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     Midazolam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    are the benzodiazepines that are best suited for sedation in the intensive care unit (ICU) because they can be administered by either intermittent or continuous infusion and have a relatively short duration of effect. Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    is used less often to sedate patients in the ICU. It can be administered by intermittent infusion, but not continuous infusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines bind to specific receptors in the gamma aminobutyric acid (GABA) receptor complex, which enhances the binding of this inhibitory neurotransmitter [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/3\">",
"     3",
"    </a>",
"    ]. Anxiolysis is achieved at low doses. Higher doses are associated with sedation, muscle relaxation, anterograde amnesia, anticonvulsant effects, and both respiratory and cardiovascular depression. Coadministration with an opioid analgesic may potentiate respiratory and cardiovascular depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Properties",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benzodiazepines are equally efficacious if they are administered in equipotent doses, but they differ in potency, rapidity of action, and duration of effect.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Potency &ndash; A benzodiazepine's potency is determined by its binding affinity for the GABA receptor.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       Lorazepam",
"      </a>",
"      has the highest binding affinity and the greatest potency.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"       Midazolam",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      have progressively lower binding affinities and potencies [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rapidity of action &ndash; A benzodiazepine's rapidity of action is related to how quickly it crosses the blood-brain barrier.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"       Midazolam",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      readily cross the blood-brain barrier because they are the highly lipophilic. Midazolam has an onset of action of 2 to 5 minutes following intravenous infusion and diazepam has a nearly immediate onset of action.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       Lorazepam",
"      </a>",
"      is less lipophilic and, therefore, has a slower onset of action of 5 to 20 minutes.",
"     </li>",
"     <li>",
"      Duration of effect &ndash; The duration of effect soon after initiating intermittent infusions differs from the duration of effect following repeated dosing. Initially, lipophilic benzodiazepines have a short duration of effect because there is rapid redistribution from the central nervous system to peripheral tissue sites. With repeated dosing, however, all benzodiazepines accumulate in adipose tissue. This increases the duration of effect because there is more drug that needs to be mobilized for elimination, particularly if a large cumulative dose was administered. Obese patients may store more drug than lean patients and are at greater risk for prolonged benzodiazepine effects. A drug's duration of effect is also influenced by the presence of active metabolites, patient factors (ie, age, body weight, hepatic function, renal function), drug interactions, and the mechanism of metabolism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     Midazolam",
"    </a>",
"    has a short duration of effect (2 to 4 hours) when it is given short-term (&lt;48 hours) by intermittent infusion to a patient with intact hepatic function because it has rapid hepatic clearance and there is rapid redistribution to peripheral tissue sites. Midazolam may cause prolonged sedation if it is administered over a longer duration because it has a large volume of distribution, binds to peripheral tissues, and has an active metabolite (alpha-hydroxymidazolam) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/5\">",
"     5",
"    </a>",
"    ]. The active metabolite is most likely to accumulate in patients who have poor hepatic or renal function or who are receiving medications that inhibit CYP3A4 metabolism (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    , macrolide antibiotics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     Lorazepam",
"    </a>",
"    has a moderate duration of effect (6 to 8 hours) when it is administered short-term (&lt;48 hours) by intermittent infusion. This duration of effect reflects lorazepam's low hepatic clearance, small volume of distribution, and absence of active metabolites [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/6\">",
"     6",
"    </a>",
"    ]. Lorazepam is a good choice for longer-term sedation because it has a low risk of drug interactions and its metabolism does not form active metabolites [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     Diazepam",
"    </a>",
"    has a short duration of effect (30 to 60 minutes) when it is administered short-term (&lt;48 hours) by intermittent infusion. This duration of effect reflects diazepam's rapid redistribution to peripheral tissue sites and hepatic clearance. Diazepam may cause prolonged sedation with repeated dosing because it has a large volume of distribution and it has two active metabolites (desmethyldiazepam and methyloxazepam). These active metabolites are most likely to accumulate in patients who are old, obese, or have renal or hepatic dysfunction.",
"   </p>",
"   <p>",
"    Tolerance (the need for an increased dose to achieve the same effect with continued administration) occurs with all benzodiazepines. It may reflect changes in the volume of distribution or in the density, binding affinity,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    occupancy of the benzodiazepine receptor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The comparative advantages and disadvantages, as well as the roles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    in critically ill patients, are described in the table (",
"    <a class=\"graphic graphic_table graphicRef79667 \" href=\"UTD.htm?19/40/20111\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Dosage regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typical dosage regimens for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef79667 \" href=\"UTD.htm?19/40/20111\">",
"     table 1",
"    </a>",
"    ). Dosing for obese patients is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32810?source=see_link\">",
"     \"Postoperative management of the critically ill obese patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory and cardiovascular depression are well known dose-dependent complications of benzodiazepines.",
"   </p>",
"   <p>",
"    Delayed awakening or excess sedation may also occur as a consequence of sedation with benzodiazepines. This appears to be most likely among patients who are sedated with benzodiazepines for longer than 48 hours. Delayed awakening is associated with prolonged mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Delirium may be a consequence of benzodiazepine therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. In an observation study of 198 mechanically ventilated patients receiving pharmacological sedation,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    was identified as an independent risk factor for delirium [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/9\">",
"     9",
"    </a>",
"    ]. Delirium appears to be more common among those who receive deep sedation (even if the deep sedation is for a short duration), are older, or have dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. It is associated with a longer duration of mechanical ventilation, ICU stay, hospital stay, and, possibly, increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients may rarely have a paradoxical reaction to benzodiazepines. This is characterized by agitation, restlessness, and hostility [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/13\">",
"     13",
"    </a>",
"    ]. Increasing the dose may worsen the agitation. The most appropriate management is to discontinue the benzodiazepine and sedate the patient with an alternative sedative.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     Haloperidol",
"    </a>",
"    is appropriate if delirium is playing a role in the agitation.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/6/41062?source=see_link\">",
"     Flumazenil",
"    </a>",
"    has been reported to reverse the paradoxical reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    may increase the risk of venous thrombosis and phlebitis at the injection site [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/16\">",
"     16",
"    </a>",
"    ]. The latter can cause injection site pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Propylene glycol toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Propylene glycol is the carrier (solvent) that is used to administer intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    . Infusion of either drug may be complicated by propylene glycol toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/17-20\">",
"     17-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Propylene glycol toxicity is characterized by hyperosmolarity and an anion gap metabolic acidosis, which is often accompanied by acute kidney injury and can progress to multisystem organ failure, if severe [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. It can occur with normal doses and renal function, but it is usually associated with dosages above the recommended range of 0.1",
"    <span class=\"nowrap\">",
"     mg/kg/hour",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    renal impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/19,21\">",
"     19,21",
"    </a>",
"    ]. An osmolar gap &gt;10",
"    <span class=\"nowrap\">",
"     mosmoles/L",
"    </span>",
"    suggests that the serum propylene glycol concentration is high enough to cause toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/22\">",
"     22",
"    </a>",
"    ]. Treatment consists of discontinuing the offending agent and, if severe, dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Propylene glycol is not the solvent for intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    . Therefore, patients who receive intravenous midazolam are not at risk for propylene glycol toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous drugs used commonly in the ICU may interact with benzodiazepines. Some increase the benzodiazepine effect, while others decrease the effect.",
"   </p>",
"   <p>",
"    Central nervous system (CNS) and respiratory depressants (eg, opioids) enhance the CNS and respiratory depressant effect of benzodiazepines. Conversely, CNS stimulants (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    ) decrease the CNS depressant effect of benzodiazepines. Many other drug interactions are related to the metabolism of benzodiazepines via the cytochrome P450 system:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"       Midazolam",
"      </a>",
"      is susceptible to interactions with drugs that either inhibit or induce CYP3A4, since CYP3A4 hydroxylates midazolam to two active metabolites, 1-hydroxy-midazolam and 3-hydroxy-midazolam. As examples, the azole antifungals (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      ) and the macrolides and related antibiotics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"       telithromycin",
"      </a>",
"      ) may prolong midazolam activity by inhibiting CYP3A4. Conversely,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      may decrease midazolam activity by inducing CYP3A4. Rifamycins (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      ) may decrease midazolam activity by increasing cytochrome P450-mediated oxidative metabolism. Hydantoins (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/51/14138?source=see_link\">",
"       fosphenytoin",
"      </a>",
"      ) may increase midazolam clearance and midazolam inhibits hydantoin clearance; the latter leads to increased serum concentrations of the hydantoins.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       Diazepam",
"      </a>",
"      is susceptible to interactions with many of the same drugs that inhibit or induce cytochrome P450 because it is hydroxylated by CYP3A4 to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27334?source=see_link\">",
"       temazepam",
"      </a>",
"      and N-demethylated by CYP3A4 and CYP2C19 to desmethyldiazepam. Temazepam and desmethyldiazepam are active metabolites that are subsequently metabolized to another active metabolite,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/50/10022?source=see_link\">",
"       oxazepam",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       Lorazepam",
"      </a>",
"      does not interact with drugs that inhibit or induce cytochrome P450 because it undergoes extensive glucuronidation in the liver to an inactive 3-O-phenolic metabolite.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ANALGESICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     Morphine sulfate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    are the intravenous opioids that are most commonly used to manage distress due to pain in critically ill patients.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/50/5927?source=see_link\">",
"     Remifentanil",
"    </a>",
"    is also an option; advantages include its rapid onset of action and prompt clearance that are independent of hepatic and renal function.",
"   </p>",
"   <p>",
"    All of the opioids lack amnestic properties, induce tolerance, and have similar analgesic and sedative properties when administered in equipotent doses [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/23\">",
"     23",
"    </a>",
"    ]. The pharmacological properties of the opioids are described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=see_link\">",
"     \"Pain control in the critically ill adult patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The comparative advantages and disadvantages, as well as the roles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/50/5927?source=see_link\">",
"     remifentanil",
"    </a>",
"    in critically ill patients, are described in the table (",
"    <a class=\"graphic graphic_table graphicRef79667 \" href=\"UTD.htm?19/40/20111\">",
"     table 1",
"    </a>",
"    ). Typical dosage regimens are also listed in the table. Dosing for obese patients is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32810?source=see_link\">",
"     \"Postoperative management of the critically ill obese patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Numerous drugs used commonly in the ICU have the potential to interact with opioids. Central nervous system (CNS) and respiratory depressants (eg, benzodiazepines) enhance the CNS and respiratory depressant effect of opioids, while CNS stimulants (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    ) decrease the CNS depressant effect of opioids. Other drug interactions are related to the metabolism of opioids via CYP3A4. As examples, the azole antifungals (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ) and the macrolides and related antibiotics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    ) may prolong",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    activity by inhibiting CYP3A4. The rifamycins (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    ) may decrease the serum concentration and effects of opioids.",
"   </p>",
"   <p>",
"    The ultrashort-acting opioids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/9/3223?source=see_link\">",
"     alfentanil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/47/15094?source=see_link\">",
"     sufentanil",
"    </a>",
"    , are generally not used in critically ill patients because they do not offer advantages and may be more costly. The long-acting opioid agonist-antagonist analgesics are also not used very often because they are long-acting and may not produce sufficient analgesia. This class of agents includes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9543?source=see_link\">",
"     butorphanol",
"    </a>",
"    , dezocine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/45/14038?source=see_link\">",
"     nalbuphine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/48/29446?source=see_link\">",
"     pentazocine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Nonsteroidal antiinflammatory analgesics are used infrequently in the ICU because they have an increased risk of side effects and no sedative properties. As an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    has been associated with potentially severe adverse effects, including platelet inhibition, renal insufficiency, and gastrointestinal bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     NEUROLEPTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroleptics are indicated for the treatment of agitation due to hyperactive delirium.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     Haloperidol",
"    </a>",
"    is used most often because it can be administered intravenously, has a mild sedative effect, and is recommended by clinical practice guidelines from the Society of Critical Care Medicine [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The availability of oral atypical antipsychotics (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    ) has stimulated interest in using them to treat ICU agitation due to hyperactive delirium. While there is some evidence that the oral atypical antipsychotics improve delirium in critically ill patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/24,25\">",
"     24,25",
"    </a>",
"    ], there is a paucity of studies comparing the efficacy and safety of oral atypical antipsychotics to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    and to one another. The few studies that exist suggest that the efficacy and safety of oral atypical antipsychotics may be similar to that of haloperidol [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/26,27\">",
"     26,27",
"    </a>",
"    ], but more rigorous studies are necessary before oral atypical antipsychotics are routinely used as an alternative to haloperidol.",
"   </p>",
"   <p>",
"    The remainder of this section focuses on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    to manage delirium in critically ill patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     Haloperidol",
"    </a>",
"    and the other neuroleptics antagonize dopamine and other neurotransmitters. However, their precise mechanism of action remains unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Properties",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     Haloperidol",
"    </a>",
"    causes dose-dependent sedation. It tends to be less sedating and have less anticholinergic activity than other neuroleptics.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapidity of onset &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       Haloperidol",
"      </a>",
"      has an onset of action 15 to 20 minutes after intravenous infusion.",
"     </li>",
"     <li>",
"      Duration of effect &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       Haloperidol",
"      </a>",
"      's duration of effect varies and depends upon the cumulative dose. Generally speaking, re-dosing may be needed 4 to 12 hours after symptoms have been controlled with the initial doses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     Haloperidol",
"    </a>",
"    is highly protein bound, has a large volume of distribution, is metabolized hepatically, and does not produce any active metabolites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Dosage regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    intravenously is common, but it has not been approved by the United States' Food and Drug Administration (FDA). The reason that it has not been approved is that intravenous administration may have a greater risk of serious adverse events than oral or intramuscular administration, most notably torsades de pointes and sudden cardiac death [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Numerous dosing regimens have been used to calm a critically ill patient with delirium, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      2 to 10 mg intravenous bolus doses administered every 20 to 30 minutes until calm is achieved (",
"      <a class=\"graphic graphic_table graphicRef79667 \" href=\"UTD.htm?19/40/20111\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A 5 mg intravenous bolus dose initially, followed by doubled doses every 20 minutes until calm is achieved [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An initial dose determined by the severity of the agitation. Examples include a 0.5 to 2 mg intravenous bolus dose for mild agitation, a 2 to 5 mg intravenous bolus dose for moderate agitation, and a 10 to 20 mg intravenous bolus dose for severe agitation. Following the initial dose, escalate the dose as needed until calm is achieved [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A continuous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      infusion beginning at a dose of 10",
"      <span class=\"nowrap\">",
"       mg/h",
"      </span>",
"      and then increasing 5",
"      <span class=\"nowrap\">",
"       mg/hr",
"      </span>",
"      every thirty minutes as needed until calm is achieved [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/31\">",
"       31",
"      </a>",
"      ]. Experience with continuous haloperidol infusion is more limited than with bolus dosing, but early indications are that the approach is probably safe and effective [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/31-33\">",
"       31-33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These regimens have not been directly compared; thus, there is no evidence that one is superior to another. In our clinical practice, we generally choose an initial dose based upon the severity of the agitation and escalate the dose as needed.",
"   </p>",
"   <p>",
"    Once calm is restored, a maintenance dose is desirable unless it appears that the delirium may quickly resolve. A reasonable approach to maintenance dosing is to administer 25 percent of the total loading dose every six hours (",
"    <a class=\"graphic graphic_table graphicRef79667 \" href=\"UTD.htm?19/40/20111\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The safe maximum daily dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    is not known. There are case reports of doses as high as 945",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/31,34\">",
"     31,34",
"    </a>",
"    ]. Doses greater than 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    have been safely administered for up to 15 consecutive days [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     Haloperidol",
"    </a>",
"    -associated polymorphic ventricular tachycardia (including torsades de pointes) is an uncommon but severe adverse reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. It is primarily associated with intermittent high dose intravenous administration. Other risk factors include a prolonged QT interval, hepatic dysfunction, electrolyte abnormalities (eg, hypokalemia, hypomagnesemia), and dilated cardiomyopathy. Patients with any of these risk factors should not receive intermittent high dose intravenous haloperidol. When intermittent haloperidol infusions are used, the QT interval should be monitored every shift (ie, every 8 to 12 hours) and haloperidol should not be given if the corrected QT interval exceeds 500 msec. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other potential side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    include acute dystonic reactions, parkinsonism, tardive dyskinesia, akathisia, and neuroleptic malignant syndrome. For unclear reasons, extrapyramidal side effects are less common among patients receiving intravenous haloperidol than among those receiving oral haloperidol [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/37\">",
"     37",
"    </a>",
"    ]. It has been hypothesized that either first-pass hepatic metabolism plays a role in the development of extrapyramidal side effects or alterations in central neurotransmitters due to parenteral haloperidol is protective [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elderly patients with dementia may have an increased risk of cardiovascular-related death (due to heart failure or sudden cardiac death) or infection-related death (due to pneumonia) when treated with atypical or typical antipsychotics. This was illustrated by a meta-analysis of 15 randomized trials (5204 patients) that found that older patients with dementia who were treated with atypical antipsychotics had an increased risk of death compared to those who received placebo (3.5 versus 2.2 percent, OR 1.54, 95% CI 1.06-2.23) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/39\">",
"     39",
"    </a>",
"    ]. These findings were supported by two subsequent studies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. The FDA has since issued a black box warning for the atypical antipsychotics. Prescribing information for all antipsychotics now includes the black box warning. Antipsychotics (typical and atypical) should be used with caution in all elderly patients with dementia, including the critically ill.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     Haloperidol",
"    </a>",
"    interacts with numerous drugs that are common in the ICU. As an example, drugs with CNS depressant effects (eg, opioids, sedatives) may enhance the CNS depressant effect of haloperidol.",
"   </p>",
"   <p>",
"    Other drug interactions are related to the metabolism of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    via the CYP3A4 and CYP2D6 pathways. These include azole antifungals and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The azole antifungals (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      ) inhibit CYP3A4, which prolongs",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      activity.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       Carbamazepine",
"      </a>",
"      induces CYP3A4, which decreases",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      activity. This effect is enhanced because haloperidol increases carbamazepine activity by inhibiting carbamazepine metabolism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rifamycins (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    ) increase cytochrome P450-mediated oxidative metabolism and decrease",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    activity. Anticholinergics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/20/11591?source=see_link\">",
"     glycopyrrolate",
"    </a>",
"    ) increase haloperidol clearance via an unknown mechanism.",
"   </p>",
"   <p>",
"    When",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    is used, other drugs that enhance the QTc-prolonging effect of haloperidol (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/58/37798?source=see_link\">",
"     artemether-lumefantrine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6472?source=see_link\">",
"     pimozide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"     thioridazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    ) should not be given.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     Metoclopramide",
"    </a>",
"    may increase haloperidol toxicity and should also not be given concurrently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PROPOFOL",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     Propofol",
"    </a>",
"    is an intravenous anesthetic that is commonly used for sedation in the ICU. It is particularly useful when rapid awakening is desirable (eg, patients who require frequent neurological examinations) because it has a short duration of effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of the sedative effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    is not well understood. However, activation of the central GABA receptors and the resulting suppression of brain activity play a central role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Properties",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     Propofol",
"    </a>",
"    (Diprivan) is a highly lipophilic phenol derivative that is insoluble in water. Therefore, it is formulated as an emulsion of soybean oil, egg lecithin, and glycerol for intravenous administration. Propofol has amnestic, anxiolytic, anticonvulsant, and muscle relaxant effects. It has no analgesic effects.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Onset of action &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"       Propofol",
"      </a>",
"      has an onset of action of less than one minute because its high lipophilicity facilitates passage through the blood-brain barrier.",
"     </li>",
"     <li>",
"      Duration of effect &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"       Propofol",
"      </a>",
"      's duration of effect is 3 to 10 minutes during short-term use (&lt;48 hours). The short duration reflects the rapid metabolism of propofol by the liver and elsewhere to minimally active metabolites, which are renally excreted. Less is known about propofol's duration of effect following long-term administration. One study reported an elimination half-life of 31 hours after prolonged administration, suggesting that propofol's high lipophilicity leads to its accumulation in fatty tissues and prolonged sedation [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The elimination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    is not impaired by hepatic or renal dysfunction. Propofol has a large volume of distribution and is highly protein bound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Dosage regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;A typical dosage regimen for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    is listed in the table (",
"    <a class=\"graphic graphic_table graphicRef79667 \" href=\"UTD.htm?19/40/20111\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     Propofol",
"    </a>",
"    is administered by continuous infusion in the ICU and not by intermittent infusion because it is associated with dose- and rate-dependent hypotension. This was best illustrated by an observational study of 25,981 patients receiving propofol anesthesia, 4079 patients (15.7 percent) developed hypotension, defined as a systolic blood pressure &lt; 90 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/43\">",
"     43",
"    </a>",
"    ]. Among those who became hypotensive, 77 percent of the hypotensive episodes occurred within 10 minutes of induction via a bolus infusion.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     Propofol",
"    </a>",
"    is generally delivered through a central venous catheter in order to avoid the pain associated with peripheral venous administration. The manufacturer recommends that the bottles and tubing be discarded every twelve hours and that line integrity be maintained in order to minimize the risk of bacterial contamination.",
"   </p>",
"   <p>",
"    During administration, serum triglycerides should be monitored in all patients who receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    in doses &ge; 50",
"    <span class=\"nowrap\">",
"     mcg/kg/min",
"    </span>",
"    for more than two days [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Alternate sedatives should be considered if hypertriglyceridemia is detected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypotension is a common consequence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    infusion, estimated to occur in approximately 25 percent of ICU patients who receive propofol for sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/46\">",
"     46",
"    </a>",
"    ]. Other potential adverse effects of propofol include bradycardia, arrhythmias, neuroexcitatory effects (seizure-like activity, myoclonus, choreoathetoid movements, meningismus), infections from contaminated vials or tubing, respiratory acidosis, pancreatitis, hypertriglyceridemia, anaphylaxis, and green or white discoloration of urine [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/42,47-50\">",
"     42,47-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unusual and potentially serious complications are associated with continuous infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    for longer than 24 to 48 hours. These include progressive hypertriglyceridemia, pancreatitis, increased carbon dioxide production, and an excessive caloric load (the emulsion contains approximately 1.1",
"    <span class=\"nowrap\">",
"     kcal/mL,",
"    </span>",
"    most of which is derived from lipids). Despite these complications, continuous infusion of propofol for greater than 24 hours does not appear to increase overall mortality, according to a meta-analysis of 14 randomized trials (1184 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Propofol infusion syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     Propofol",
"    </a>",
"    infusion syndrome (PRIS) is a rare complication of propofol infusion. It is associated with high doses (&gt;4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour or &gt;67",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute) and prolonged use (&gt;48 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Additional proposed risk factors include a young age, critical illness, high fat and low carbohydrate intake, inborn errors of mitochondrial fatty acid oxidation, and concomitant catecholamine infusion or steroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/54\">",
"     54",
"    </a>",
"    ]. Characteristics of PRIS include acute refractory bradycardia, severe metabolic acidosis, cardiovascular collapse, rhabdomyolysis, hyperlipidemia, renal failure, and hepatomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/53,55\">",
"     53,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of PRIS is unknown, but it is probably less than 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/56\">",
"     56",
"    </a>",
"    ]. Mortality appears to be high, exceeding 60 percent in a case series of 61 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/53\">",
"     53",
"    </a>",
"    ]. Treatment involves discontinuation of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    infusion and supportive care [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;CNS and respiratory depressants (eg, opioid narcotics, sedatives) enhance the CNS and respiratory depressant effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    . Propofol undergoes hepatic conjugation to inactive metabolites; thus, metabolically-related drug interactions of major clinical importance have not been identified. Co-administration of propofol with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/9/3223?source=see_link\">",
"     alfentanil",
"    </a>",
"    increases the risk of opisthotonus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    grand mal seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     DEXMEDETOMIDINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/53/33622?source=see_link\">",
"     Dexmedetomidine",
"    </a>",
"    is a highly selective, centrally acting alpha-2-agonist with anxiolytic, sedative, and some analgesic effects. It has no deleterious effects on the respiratory drive. According to the United States' Food and Drug Administration (FDA), dexmedetomidine is indicated for initial sedation of mechanically ventilated patients for up to 24 hours. The rationale for the 24 hour limit is that longer use may increase the risk of withdrawal effects (eg, hypertension), although these effects have not been consistently found in studies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evidence suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/53/33622?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    decreases the need for alternative sedatives [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/59\">",
"     59",
"    </a>",
"    ] and increases the number of days without delirium [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. It also appears to decrease the duration of mechanical ventilation when compared with benzodiazepines [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/61,62\">",
"     61,62",
"    </a>",
"    ], but not when compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/61\">",
"     61",
"    </a>",
"    ]. Dexmedetomidine has not been shown to reduce the length of ICU stay, length of hospital stay, or mortality.",
"   </p>",
"   <p>",
"    These findings were best illustrated by two randomized trials, the MIDEX trial and the PRODEX trial. The multicenter MIDEX trial randomly assigned 500 mechanically ventilated patients who needed light to moderate sedation for more than 24 hours to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/53/33622?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/61\">",
"     61",
"    </a>",
"    ]. The dexmedetomidine group had a shorter duration of mechanical ventilation (123 versus 164 hours), but there was no difference in the length of ICU stay, length of hospital stay, or mortality. Similarly, the multicenter PRODEX trial randomly assigned 498 patients who needed light to moderate sedation for more than 24 hours to receive dexmedetomidine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/61\">",
"     61",
"    </a>",
"    ]. There were no differences in the duration of mechanical ventilation, length of ICU stay, length of hospital stay, or mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Dosage regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;An initial loading dose is not frequently used [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/63\">",
"     63",
"    </a>",
"    ]. The reason is that a loading dose may cause transient hypotension or hypertension, depending upon whether vasodilation from activation of central alpha 2a receptors or vasoconstriction from activation of peripheral alpha 2b receptors predominates.",
"   </p>",
"   <p>",
"    The usual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/53/33622?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    maintenance dose is 0.2 to 0.7",
"    <span class=\"nowrap\">",
"     mcg/kg/hour,",
"    </span>",
"    with dosage increases no more frequently than every 30 minutes. Use of doses up to 1.4",
"    <span class=\"nowrap\">",
"     mcg/kg/hr",
"    </span>",
"    have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/60,62\">",
"     60,62",
"    </a>",
"    ]. However, doses &gt;1.5",
"    <span class=\"nowrap\">",
"     mcg/kg/hr",
"    </span>",
"    do not appear to add to dexmedetomidine's clinical efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no specific guidelines for modifying the dose for elderly patients or patients who have renal or hepatic impairment. It is prudent to start at the low end of the dosage range and titrate slowly based upon the patient's response.",
"   </p>",
"   <p>",
"    The advantages, disadvantages, role, and dosage regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/53/33622?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    are described in the table (",
"    <a class=\"graphic graphic_table graphicRef79667 \" href=\"UTD.htm?19/40/20111\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential adverse events during sedation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/53/33622?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    include hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/61\">",
"     61",
"    </a>",
"    ], hypertension, nausea, bradycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/61\">",
"     61",
"    </a>",
"    ], and atrial fibrillation. Refractory cardiogenic shock has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;CNS and respiratory depressants (eg, opioid narcotics, sedatives) enhance the CNS and respiratory depressant effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/53/33622?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    . Although dexmedetomidine is metabolized by glucuronidation and cytochrome P450, clinically important cytochrome P450-mediated drug interactions have not been identified. Drugs that lower systemic blood pressure may enhance dexmedetomidine's hypotensive effect, while drugs that increase systemic blood pressure may enhance dexmedetomidine's hypertensive effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     BARBITURATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"     Thiopental",
"    </a>",
"    (Pentothal) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/15/24823?source=see_link\">",
"     methohexital",
"    </a>",
"    (Brevital) are barbiturates that are occasionally used to sedate critically ill patients. Barbiturates produce sedation by binding to the GABA-receptor complex via a different receptor from benzodiazepines. They commonly cause hypotension and may produce profound cardiovascular and respiratory depression. As a result, the use of barbiturates should be limited to patients not tolerating or responding to other agents. Other undesirable characteristics of barbiturates include prolonged elimination half-lives, induction of the cytochrome p-450 enzyme system, and accumulation of drugs in renal and hepatic dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27695572\">",
"    <span class=\"h1\">",
"     FOSPROPOFOL",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24741?source=see_link\">",
"     Fospropofol",
"    </a>",
"    is a water-soluble",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    prodrug approved by the United States Food and Drug Administration (FDA) for monitored anesthesia care (MAC) sedation in adults undergoing diagnostic or therapeutic procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/66\">",
"     66",
"    </a>",
"    ]. Fospropofol is metabolized by alkaline phosphatases to propofol, formaldehyde, and phosphate. The formaldehyde is then metabolized by tissue enzymes to formate, which is oxidized to carbon dioxide.",
"   </p>",
"   <p>",
"    In an open-label multicenter trial, 60 mechanically ventilated medical or surgical patients were randomly assigned to receive fospropfol by IV bolus plus infusion,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24741?source=see_link\">",
"     fospropofol",
"    </a>",
"    by infusion only, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    by infusion only for up to twelve hours [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/67\">",
"     67",
"    </a>",
"    ]. All three groups were permitted an increased infusion rate for agitation. Fospropofol was well-tolerated and effective for short-term sedation. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27695579\">",
"    <span class=\"h1\">",
"     SEVOFLURANE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/47/23286?source=see_link\">",
"     Sevoflurane",
"    </a>",
"    , a polyfluorinated methyl-isopropyl compound, is a volatile inhalational anesthetic that is being evaluated as a potential sedative agent for ICU patients. Ninety-five to 98 percent of sevoflurane is eliminated through the lungs, while the remaining 2 to 5 percent undergoes rapid hepatic metabolism to inorganic fluoride and hexafluoroisopropanol (HFIP) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/68\">",
"     68",
"    </a>",
"    ]. HFIP in the blood is conjugated by glucuronic acid and then secreted by the kidney.",
"   </p>",
"   <p>",
"    Potential advantages of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/47/23286?source=see_link\">",
"     sevoflurane",
"    </a>",
"    as a sedating agent for critically ill ICU patients include the short duration of action and rapid elimination [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/69\">",
"     69",
"    </a>",
"    ]. Potential disadvantages include fluoride accumulation with prolonged use (especially in patients with impaired renal function) and malignant hyperthermia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/69\">",
"     69",
"    </a>",
"    ]. Additionally, sevoflurane undergoes degradation on contact with alkaline carbon dioxide absorbants used to remove carbon dioxide from the circuit, to a potentially nephrotoxic product (trifluoromethyl vinly ether; Compound A) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/68\">",
"     68",
"    </a>",
"    ]. Administration of volatile anesthetic agents in the ICU is not a standard practice; investments in technology and clinician education will be required before sevoflurane can be used as a routine sedative in critically ill patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32984?source=see_link\">",
"     \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36921?source=see_link\">",
"     \"Susceptibility to malignant hyperthermia\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    A trial randomly assigned 60 mechanically ventilated ICU patients to sedation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/47/23286?source=see_link\">",
"     sevoflurane",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/70\">",
"     70",
"    </a>",
"    ]. All of the patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/50/5927?source=see_link\">",
"     remifentanil",
"    </a>",
"    for analgesia, most were relatively young trauma patients, and 47 completed the trial. The median duration of sedation in the sevoflurane group was 50 hours (range 39 to 71 hours). Wake-up time and time to extubation were significantly shorter in the sevoflurane group compared with the propofol or midazolam groups. The study had too few events to conclusively detect differences in ICU length of stay or mortality. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     COMPARISONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is insufficient evidence to recommend any sedation regimen over another, since relatively few trials have directly compared sedative agents. Comparing agents across trials is invalid because there are differences in the severity of illness, types of cases, therapeutic goals, duration of therapy, and techniques to assess sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following direct comparisons are among the few that have been reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"       Midazolam",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      &ndash; Several studies have compared midazolam to propofol, with both drugs providing adequate sedation [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/71-76\">",
"       71-76",
"      </a>",
"      ]. Recovery time was longer for midazolam than propofol after brief use, but was prolonged for both drugs following long-term administration. Adverse effects related to hemodynamics or oxygen delivery were uncommon.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       Lorazepam",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      &ndash; In an open-label trial, 132 mechanically ventilated patients were randomly assigned to receive lorazepam by intermittent intravenous bolus or propofol by continuous infusion [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/77\">",
"       77",
"      </a>",
"      ]. Median days on mechanical ventilation were lower in the propofol group (six versus eight days). Among hospital survivors, the difference was greater (four versus nine days). There was no mortality difference. The trial has been criticized for its design because it is unclear whether the results are due to the different medications or different types of administration (intermittent boluses versus continuous infusion).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/53/33622?source=see_link\">",
"       Dexmedetomidine",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      &ndash; A trial randomly assigned 89 postoperative patients with an expected length of intubation of &lt;24 hours to receive dexmedetomidine or propofol for sedation [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/78\">",
"       78",
"      </a>",
"      ]. Both groups were permitted to receive as-needed",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine sulfate",
"      </a>",
"      . The dexmedetomidine group was less deeply sedated and had a shorter duration of intubation, but also had more discomfort. There was no difference in patient satisfaction or the amount of midazolam or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      received.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/53/33622?source=see_link\">",
"       Dexmedetomidine",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      &ndash; A multicenter trial randomly assigned 375 patients who were expected to be mechanically ventilated for more than 24 hours to receive dexmedetomidine or midazolam for either 30 days or until extubation [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/62\">",
"       62",
"      </a>",
"      ]. There was no difference in the amount of time spent within the goal sedation range, the trial's primary endpoint. The dexmedetomidine group had a significantly lower prevalence of delirium (54 versus 77 percent) and shorter duration until extubation (3.7 versus 5.6 days), although these benefits came at a cost of more frequent bradycardia (42 versus 19 percent). Important limitations of the trial were the high starting dose of midazolam (approximately 5",
"      <span class=\"nowrap\">",
"       mg/hour),",
"      </span>",
"      the lack of daily interruption of the sedative infusions, and the high dexmedetomidine dose (up to twice the currently FDA-approved dose) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dexmedotomidine versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      &ndash; In a double-blind trial, 106 adults who were being mechanically ventilated in a medical and surgical ICU were randomly assigned to receive dexmedotomidine or lorazepam for sedation for up to 120 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/60\">",
"       60",
"      </a>",
"      ]. The dosages were titrated using the Richmond Agitation Sedation Scale (RASS) and patients were monitored twice daily for delirium with the Confusion Assessment Method for the ICU (CAM-ICU). The dexmedotomidine group spent more time within one RASS point of the sedation goal and had more days without delirium or coma. The results may have been confounded because patients in the dexmedotomidine group received four times as much",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      per day than patients in the lorazepam group.",
"     </li>",
"     <li>",
"      Dexmedotomidine versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      &ndash; In an open-label trial, 20 medical or surgical ICU patients with agitated delirium that prevented extubation were randomly assigned to receive haloperidol (0.5 to 2",
"      <span class=\"nowrap\">",
"       mg/hr)",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/53/33622?source=see_link\">",
"       dexmedetomidine",
"      </a>",
"      (0.2 to 0.7",
"      <span class=\"nowrap\">",
"       mcg/kg/hr)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/80\">",
"       80",
"      </a>",
"      ]. Loading doses were at the discretion of the prescribing clinician. Dexmedotomidine shortened the median time to extubation and decreased the length of stay in the ICU.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These trials indicate that no sedative-analgesic agent is sufficiently superior to other agents to warrant its use in all clinical situations. As a result, selection of an agent must be individualized according to patient characteristics and the clinical situation, as described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15833?source=see_link&amp;anchor=H8#H8\">",
"     \"Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal\", section on 'Selection of an agent'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     COMBINATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many clinicians believe that combination therapy using different types of sedatives is best. The rationale is that agitation is often multifactorial and each potential cause deserves a targeted therapy. This notion was supported by a trial that randomly assigned 30 mechanically ventilated patients to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    alone or midazolam plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/31/25082/abstract/81\">",
"     81",
"    </a>",
"    ]. Midazolam plus fentanyl maintained sedation level goals better, decreased the dose of the primary agent, added analgesia, and did not appreciably increase the likelihood of prolonged sedation. There were no differences in hemodynamic or respiratory adverse effects. Two patients treated with the combination regimen developed ileus, compared to none with midazolam alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15833?source=see_link\">",
"     \"Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Distress is common among critically ill patients. It generally presents as agitation and can have untoward physiological effects. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Classes of sedative-analgesic medications used to treat distress include benzodiazepines, opioids, neuroleptics,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/53/33622?source=see_link\">",
"       dexmedetomidine",
"      </a>",
"      , and, rarely, barbiturates. Pilot studies of the propofol prodrug",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24741?source=see_link\">",
"       fospropofol",
"      </a>",
"      and the volatile anesthetic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/47/23286?source=see_link\">",
"       sevoflurane",
"      </a>",
"      have been reported. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Benzodiazepines'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Analgesics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Neuroleptics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Propofol'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Dexmedetomidine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H29\">",
"       'Barbiturates'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27695572\">",
"       'Fospropofol'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27695579\">",
"       'Sevoflurane'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is little evidence to guide the selection of one pharmacological sedation regimen over another, since few trials have directly compared sedative-analgesic agents. The etiology of the distress, the expected duration of therapy, potential interactions with other drugs, the desired depth of sedation, and pharmacokinetic modifying factors are important considerations whenever selecting an agent. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Comparisons'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31\">",
"       'Combination therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15833?source=see_link&amp;anchor=H8#H8\">",
"       \"Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal\", section on 'Selection of an agent'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dose-dependent respiratory and cardiovascular depression are common among sedative-analgesic agents. Most classes of sedative-analgesics also have unique adverse effects. Examples include propylene glycol toxicity and the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      infusion syndrome. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Propylene glycol toxicity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Propofol infusion syndrome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/1\">",
"      Hansen-Flaschen J. Improving patient tolerance of mechanical ventilation. Challenges ahead. Crit Care Clin 1994; 10:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/2\">",
"      Lewis KS, Whipple JK, Michael KA, Quebbeman EJ. Effect of analgesic treatment on the physiological consequences of acute pain. Am J Hosp Pharm 1994; 51:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/3\">",
"      M&ouml;hler H, Richards JG. The benzodiazepine receptor: a pharmacological control element of brain function. Eur J Anaesthesiol Suppl 1988; 2:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/4\">",
"      Arendt RM, Greenblatt DJ, deJong RH, et al. In vitro correlates of benzodiazepine cerebrospinal fluid uptake, pharmacodynamic action and peripheral distribution. J Pharmacol Exp Ther 1983; 227:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/5\">",
"      Ziegler WH, Schalch E, Leishman B, Eckert M. Comparison of the effects of intravenously administered midazolam, triazolam and their hydroxy metabolites. Br J Clin Pharmacol 1983; 16 Suppl 1:63S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/6\">",
"      Greenblatt DJ. Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet 1981; 6:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/7\">",
"      Jacobi J, Fraser GL, Coursin DB, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 2002; 30:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/8\">",
"      Kollef MH, Levy NT, Ahrens TS, et al. The use of continuous i.v. sedation is associated with prolongation of mechanical ventilation. Chest 1998; 114:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/9\">",
"      Pandharipande P, Shintani A, Peterson J, et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology 2006; 104:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/10\">",
"      Jones C, B&auml;ckman C, Capuzzo M, et al. Precipitants of post-traumatic stress disorder following intensive care: a hypothesis generating study of diversity in care. Intensive Care Med 2007; 33:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/11\">",
"      Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA 2004; 291:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/12\">",
"      Pisani MA, Murphy TE, Araujo KL, et al. Benzodiazepine and opioid use and the duration of intensive care unit delirium in an older population. Crit Care Med 2009; 37:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/13\">",
"      Litchfield NB. Complications of Intravenous Diazepam - Adverse Psychological Reactions. (An assessment of 16,000 cases). Anesth Prog 1980; 27:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/14\">",
"      Thurston TA, Williams CG, Foshee SL. Reversal of a paradoxical reaction to midazolam with flumazenil. Anesth Analg 1996; 83:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/15\">",
"      Fulton SA, Mullen KD. Completion of upper endoscopic procedures despite paradoxical reaction to midazolam: a role for flumazenil? Am J Gastroenterol 2000; 95:809.",
"     </a>",
"    </li>",
"    <li>",
"     Diazepam injection [Baxter Healthcare Corporation] United States Food and Drug Administration approved prescribing information. file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=1045 (Accessed on May 12, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/17\">",
"      Tayar J, Jabbour G, Saggi SJ. Severe hyperosmolar metabolic acidosis due to a large dose of intravenous lorazepam. N Engl J Med 2002; 346:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/18\">",
"      Cawley MJ. Short-term lorazepam infusion and concern for propylene glycol toxicity: case report and review. Pharmacotherapy 2001; 21:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/19\">",
"      Wilson KC, Reardon C, Theodore AC, Farber HW. Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: a case series and prospective, observational pilot study. Chest 2005; 128:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/20\">",
"      Wilson KC, Reardon C, Farber HW. Propylene glycol toxicity in a patient receiving intravenous diazepam. N Engl J Med 2000; 343:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/21\">",
"      Arroliga AC, Shehab N, McCarthy K, Gonzales JP. Relationship of continuous infusion lorazepam to serum propylene glycol concentration in critically ill adults. Crit Care Med 2004; 32:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/22\">",
"      Barnes BJ, Gerst C, Smith JR, et al. Osmol gap as a surrogate marker for serum propylene glycol concentrations in patients receiving lorazepam for sedation. Pharmacotherapy 2006; 26:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/23\">",
"      Veselis RA, Reinsel RA, Feshchenko VA, Wro��ski M. The comparative amnestic effects of midazolam, propofol, thiopental, and fentanyl at equisedative concentrations. Anesthesiology 1997; 87:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/24\">",
"      Devlin JW, Roberts RJ, Fong JJ, et al. Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. Crit Care Med 2010; 38:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/25\">",
"      Seem&uuml;ller F, Volkmer E, Vogel T, et al. Quetiapine as treatment for delirium during weaning from ventilation: a case report. J Clin Psychopharmacol 2007; 27:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/26\">",
"      Skrobik YK, Bergeron N, Dumont M, Gottfried SB. Olanzapine vs haloperidol: treating delirium in a critical care setting. Intensive Care Med 2004; 30:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/27\">",
"      Han CS, Kim YK. A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics 2004; 45:297.",
"     </a>",
"    </li>",
"    <li>",
"     Information for Healthcare Professionals: Haloperidol file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/ucm085203.htm (Accessed on May 12, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/29\">",
"      Adams F. Emergency intravenous sedation of the delirious, medically ill patient. J Clin Psychiatry 1988; 49 Suppl:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/30\">",
"      Fish DN. Treatment of delirium in the critically ill patient. Clin Pharm 1991; 10:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/31\">",
"      Riker RR, Fraser GL, Cox PM. Continuous infusion of haloperidol controls agitation in critically ill patients. Crit Care Med 1994; 22:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/32\">",
"      Fernandez F, Holmes VF, Adams F, Kavanaugh JJ. Treatment of severe, refractory agitation with a haloperidol drip. J Clin Psychiatry 1988; 49:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/33\">",
"      Seneff MG, Mathews RA. Use of haloperidol infusions to control delirium in critically ill adults. Ann Pharmacother 1995; 29:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/34\">",
"      Stern TA. The management of depression and anxiety following myocardial infarction. Mt Sinai J Med 1985; 52:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/35\">",
"      Metzger E, Friedman R. Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. J Clin Psychopharmacol 1993; 13:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/36\">",
"      Wilt JL, Minnema AM, Johnson RF, Rosenblum AM. Torsade de pointes associated with the use of intravenous haloperidol. Ann Intern Med 1993; 119:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/37\">",
"      Menza MA, Murray GB, Holmes VF, Rafuls WA. Decreased extrapyramidal symptoms with intravenous haloperidol. J Clin Psychiatry 1987; 48:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/38\">",
"      Korpi ER, Kleinman JE, Costakos DT, et al. Reduced haloperidol in the post-mortem brains of haloperidol-treated patients. Psychiatry Res 1984; 11:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/39\">",
"      Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/40\">",
"      Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007; 146:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/41\">",
"      Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007; 176:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/42\">",
"      Fulton B, Sorkin EM. Propofol. An overview of its pharmacology and a review of its clinical efficacy in intensive care sedation. Drugs 1995; 50:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/43\">",
"      Hug CC Jr, McLeskey CH, Nahrwold ML, et al. Hemodynamic effects of propofol: data from over 25,000 patients. Anesth Analg 1993; 77:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/44\">",
"      Devlin JW, Lau AK, Tanios MA. Propofol-associated hypertriglyceridemia and pancreatitis in the intensive care unit: an analysis of frequency and risk factors. Pharmacotherapy 2005; 25:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/45\">",
"      Devaud JC, Berger MM, Pannatier A, et al. Hypertriglyceridemia: a potential side effect of propofol sedation in critical illness. Intensive Care Med 2012; 38:1990.",
"     </a>",
"    </li>",
"    <li>",
"     Diprivan package insert. Astra Zeneca. August 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/47\">",
"      Bennett SN, McNeil MM, Bland LA, et al. Postoperative infections traced to contamination of an intravenous anesthetic, propofol. N Engl J Med 1995; 333:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/48\">",
"      Mirenda J. Prolonged propofol sedation in the critical care unit. Crit Care Med 1995; 23:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/49\">",
"      Blakey SA, Hixson-Wallace JA. Clinical significance of rare and benign side effects: propofol and green urine. Pharmacotherapy 2000; 20:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/50\">",
"      Nates J, Avidan A, Gozal Y, Gertel M. Appearance of white urine during propofol anesthesia. Anesth Analg 1995; 81:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/51\">",
"      Ho KM, Ng JY. The use of propofol for medium and long-term sedation in critically ill adult patients: a meta-analysis. Intensive Care Med 2008; 34:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/52\">",
"      McKeage K, Perry CM. Propofol: a review of its use in intensive care sedation of adults. CNS Drugs 2003; 17:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/53\">",
"      Kam PC, Cardone D. Propofol infusion syndrome. Anaesthesia 2007; 62:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/54\">",
"      Diedrich DA, Brown DR. Analytic reviews: propofol infusion syndrome in the ICU. J Intensive Care Med 2011; 26:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/55\">",
"      Fong JJ, Sylvia L, Ruthazer R, et al. Predictors of mortality in patients with suspected propofol infusion syndrome. Crit Care Med 2008; 36:2281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/56\">",
"      Crozier TA. The 'propofol infusion syndrome': myth or menace? Eur J Anaesthesiol 2006; 23:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/57\">",
"      Shehabi Y, Ruettimann U, Adamson H, et al. Dexmedetomidine infusion for more than 24 hours in critically ill patients: sedative and cardiovascular effects. Intensive Care Med 2004; 30:2188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/58\">",
"      Buck ML, Willson DF. Use of dexmedetomidine in the pediatric intensive care unit. Pharmacotherapy 2008; 28:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/59\">",
"      Venn RM, Bradshaw CJ, Spencer R, et al. Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. Anaesthesia 1999; 54:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/60\">",
"      Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA 2007; 298:2644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/61\">",
"      Jakob SM, Ruokonen E, Grounds RM, et al. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA 2012; 307:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/62\">",
"      Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA 2009; 301:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/63\">",
"      Dasta JF, Kane-Gill SL, Durtschi AJ. Comparing dexmedetomidine prescribing patterns and safety in the naturalistic setting versus published data. Ann Pharmacother 2004; 38:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/64\">",
"      Venn M, Newman J, Grounds M. A phase II study to evaluate the efficacy of dexmedetomidine for sedation in the medical intensive care unit. Intensive Care Med 2003; 29:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/65\">",
"      Sichrovsky TC, Mittal S, Steinberg JS. Dexmedetomidine sedation leading to refractory cardiogenic shock. Anesth Analg 2008; 106:1784.",
"     </a>",
"    </li>",
"    <li>",
"     Lusedra package insert. Eisai R&amp;D management C., Ltd. 10/09.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/67\">",
"      Candiotti KA, Gan TJ, Young C, et al. A randomized, open-label study of the safety and tolerability of fospropofol for patients requiring intubation and mechanical ventilation in the intensive care unit. Anesth Analg 2011; 113:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/68\">",
"      Behne M, Wilke HJ, Harder S. Clinical pharmacokinetics of sevoflurane. Clin Pharmacokinet 1999; 36:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/69\">",
"      Bracco D, Donatelli F. Volatile agents for ICU sedation? Intensive Care Med 2011; 37:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/70\">",
"      Mesnil M, Capdevila X, Bringuier S, et al. Long-term sedation in intensive care unit: a randomized comparison between inhaled sevoflurane and intravenous propofol or midazolam. Intensive Care Med 2011; 37:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/71\">",
"      Ostermann ME, Keenan SP, Seiferling RA, Sibbald WJ. Sedation in the intensive care unit: a systematic review. JAMA 2000; 283:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/72\">",
"      Aitkenhead AR, Pepperman ML, Willatts SM, et al. Comparison of propofol and midazolam for sedation in critically ill patients. Lancet 1989; 2:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/73\">",
"      Carrasco G, Molina R, Costa J, et al. Propofol vs midazolam in short-, medium-, and long-term sedation of critically ill patients. A cost-benefit analysis. Chest 1993; 103:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/74\">",
"      Pohlman AS, Simpson KP, Hall JB. Continuous intravenous infusions of lorazepam versus midazolam for sedation during mechanical ventilatory support: a prospective, randomized study. Crit Care Med 1994; 22:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/75\">",
"      Chamorro C, de Latorre FJ, Montero A, et al. Comparative study of propofol versus midazolam in the sedation of critically ill patients: results of a prospective, randomized, multicenter trial. Crit Care Med 1996; 24:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/76\">",
"      Barrientos-Vega R, Mar S&aacute;nchez-Soria M, Morales-Garc&iacute;a C, et al. Prolonged sedation of critically ill patients with midazolam or propofol: impact on weaning and costs. Crit Care Med 1997; 25:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/77\">",
"      Carson SS, Kress JP, Rodgers JE, et al. A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients. Crit Care Med 2006; 34:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/78\">",
"      Corbett SM, Rebuck JA, Greene CM, et al. Dexmedetomidine does not improve patient satisfaction when compared with propofol during mechanical ventilation. Crit Care Med 2005; 33:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/79\">",
"      Wunsch H, Kress JP. A new era for sedation in ICU patients. JAMA 2009; 301:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/80\">",
"      Reade MC, O'Sullivan K, Bates S, et al. Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial. Crit Care 2009; 13:R75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/31/25082/abstract/81\">",
"      Richman PS, Baram D, Varela M, Glass PS. Sedation during mechanical ventilation: a trial of benzodiazepine and opiate in combination. Crit Care Med 2006; 34:1395.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1616 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A20BFA4EA1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_31_25082=[""].join("\n");
var outline_f24_31_25082=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BENZODIAZEPINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Properties",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Dosage regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Propylene glycol toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ANALGESICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      NEUROLEPTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Properties",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Dosage regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PROPOFOL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Properties",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Dosage regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Propofol infusion syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      DEXMEDETOMIDINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Dosage regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      BARBITURATES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27695572\">",
"      FOSPROPOFOL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27695579\">",
"      SEVOFLURANE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      COMPARISONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      COMBINATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1616\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1616|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/40/20111\" title=\"table 1\">",
"      Sedative dosage regimens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32984?source=related_link\">",
"      Malignant hyperthermia: Clinical diagnosis and management of acute crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=related_link\">",
"      Pain control in the critically ill adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32810?source=related_link\">",
"      Postoperative management of the critically ill obese patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15833?source=related_link\">",
"      Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36921?source=related_link\">",
"      Susceptibility to malignant hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43720?source=related_link\">",
"      Use of neuromuscular blocking medications in critically ill patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_31_25083="Classification DILI";
var content_f24_31_25083=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classifications of drug-induced liver injury",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of classification",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examples",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Clinical laboratory",
"       </td>",
"       <td>",
"        Hepatocellular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholestatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mixed hepatocellular/cholestatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Mechanism of hepatotoxicity",
"       </td>",
"       <td>",
"        Direct hepatotoxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Idiosyncratic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Immune-mediated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Metabolic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        Histologic findings",
"       </td>",
"       <td>",
"        Cellular necrosis or apoptosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholestasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Steatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phospholipidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulomatous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sinuoidal obstruction syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_31_25083=[""].join("\n");
var outline_f24_31_25083=null;
var title_f24_31_25084="Patch breakthru bleeding";
var content_f24_31_25084=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Breakthrough bleeding and breakthrough bleeding/spotting by cycle",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Non-comparative trial",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Comparative trial",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Patch* (N = 1664), percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       Patch* (N = 812), percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       OC&bull; (N = 605), percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"4\">",
"       Breakthrough bleeding",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Cycle 1",
"      </td>",
"      <td>",
"       3.7",
"      </td>",
"      <td>",
"       3.7",
"      </td>",
"      <td>",
"       4.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Cycle 3",
"      </td>",
"      <td>",
"       3.7",
"      </td>",
"      <td>",
"       2.9",
"      </td>",
"      <td>",
"       4.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Cycle 6",
"      </td>",
"      <td>",
"       2.5",
"      </td>",
"      <td>",
"       2.7",
"      </td>",
"      <td>",
"       3.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Cycle 9",
"      </td>",
"      <td>",
"       1.5",
"      </td>",
"      <td>",
"       1.3",
"      </td>",
"      <td>",
"       3.1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Cycle 13",
"      </td>",
"      <td>",
"       1.7",
"      </td>",
"      <td>",
"       0.0",
"      </td>",
"      <td>",
"       2.4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"4\">",
"       Breakthrough bleeding and/or spotting",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Cycle 1",
"      </td>",
"      <td>",
"       17.5",
"      </td>",
"      <td>",
"       18.3",
"      </td>",
"      <td>",
"       11.4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Cycle 3",
"      </td>",
"      <td>",
"       11.1",
"      </td>",
"      <td>",
"       10.0",
"      </td>",
"      <td>",
"       8.8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Cycle 6",
"      </td>",
"      <td>",
"       7.3",
"      </td>",
"      <td>",
"       9.5",
"      </td>",
"      <td>",
"       7.1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Cycle 9",
"      </td>",
"      <td>",
"       6.5",
"      </td>",
"      <td>",
"       6.7",
"      </td>",
"      <td>",
"       4.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Cycle 13",
"      </td>",
"      <td>",
"       9.2",
"      </td>",
"      <td>",
"       5.5",
"      </td>",
"      <td>",
"       7.1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Patch: transdermal contraceptive patch.",
"     <br>",
"      &bull; OC: oral contraceptive (triphasic preparation with levonorgestrel as progestin).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Burkman, RT. The transdermal contraceptive patch: a new approach to hormonal contraception. Int J Fertil Womens Med. 2002; 47(2): 69-76. Copyright &copy; 2002 MSP International, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_31_25084=[""].join("\n");
var outline_f24_31_25084=null;
var title_f24_31_25085="Efer Dumon rigid bronchoscope";
var content_f24_31_25085=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Efer-Dumon bronchoscopes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 148px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCACUAWYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5sPiPXM/8hnUv/Ap/8aP+Ej1z/oM6l/4FP/jWVQKANX/hI9c/6DOpf+BT/wCNJ/wkeuf9BnUv/Ap/8ayqKANUeI9c/wCgzqX/AIFP/jS/8JHrn/QZ1L/wKf8AxrJ70vagDV/4SPXMf8hnUv8AwKf/ABpf+Ej1v/oM6l/4FP8A41k0ooA1f+Ej1v8A6DOpf+BT/wCNH/CR63/0GdS/8Cn/AMayqO9AGr/wket/9BnUv/Ap/wDGj/hI9c/6DOpf+BT/AONZQooA1f8AhI9c/wCgzqX/AIFP/jR/wket/wDQZ1L/AMCn/wAayqSgDW/4SPW/+gzqX/gU/wDjR/wket/9BnUv/Ap/8ayjSUAa3/CR63/0GdS/8Cn/AMaP+Ej1v/oM6l/4FP8A41k0UAax8R63/wBBnUv/AAKf/Gj/AISPXP8AoM6l/wCBT/41k0UAan/CR65/0GdS/wDAp/8AGj/hI9b/AOgzqX/gU/8AjWXRQBqjxHref+QzqX/gU/8AjS/8JHrn/QZ1L/wKf/GsnNGaANb/AISPW/8AoM6l/wCBT/40f8JHrf8A0GdS/wDAp/8AGsmloA1f+Ej1v/oM6l/4FP8A40f8JHref+QzqX/gU/8AjWVR3oA1f+Ej1v8A6DOpf+BT/wCNH/CR65/0GdS/8Cn/AMayaWgDVPiPXP8AoM6l/wCBT/40n/CR65/0GdS/8Cn/AMayzSdDQBqnxHrn/QZ1L/wKf/Gk/wCEj1z/AKDOpf8AgU/+NZZpKANX/hI9c/6DOpf+BT/40v8Awkeuf9BnUv8AwKk/xrKooA1T4j1vP/IZ1L/wKf8Axo/4SPXM/wDIZ1L/AMCn/wAayaUdaANUeI9b/wCgzqX/AIFP/jR/wkeuY/5DOpf+BT/41ldj6UelAGr/AMJHrmONZ1L/AMCn/wAaP+Ej1z/oM6l/4FP/AI1lUUAap8R64TxrOpf+BT/40v8Awkmtj/mM6l/4FP8A41lUlAGqPEet99Z1L/wKf/Gisnp1FFAC0UlHbmgBaTvS0hoAWjtQepoPSgAooooAO9HekpaADtRRRQAtJRSUAKaKQ0elAC0UmaUUAFHeigdaAFA5o78UtIO1ACUlKetFABSD3opaACjvSUUALRRRQAppKDSUALQetFFAB3oHWjHNAPSgBTQKDSCgBRR3oPrQOlAB24pKUfWkFAAetL24o70YzQAlFFFACUuaKMUAFHeil70ADdTQelH8qU+lADaQUveigBKKX+GgDH1oAKKXrRzQAgoxzzS45paAGgUoFFFABjiijrRQAvak4ooHWgAzRmnYooAbRwKMcUYoAMUY/Kg5oBoAQCjGDTqKAG9qTtT6bigA70lFKetACCloUUuBQAHnFKKBRQAnTAope9AoATtR/LFL6UUAIOtFLik9KADpR3o/nR2oABz1oo+lFADaUUUYoAUUvekPTivS1t/hd5CJ9s1zzB1kaL73vgcCgDzSlr0WTTvhk5+XXdai9f8AQ939aQ6N8M9uR4s1rPp/Zv8A9egDzr0or0aPQ/hxI+0eLdVX3ewwP50T+FvArLi18ZuG/wCmtsQP0oA85FFd4vg3w9IP3fjfTQSeN8TirVr8OdNuWjWLxtomXIUbgw5NAHnXpSV6sfhArxb4vGGgsO37zFN/4U3f7cxeINDkB6EXKj+tAHldGK9Gl+EmuAgQ3+iy89r5B/WrVp8E/FkxVglhJGe8V4hNAHl+KXFept8C/G3WCwgkQ9MXCknjnpVOT4MeOlbH9iOT/suDQB5uAKXPHSu+l+EXjqI8+Hrtv93B/rVY/C3xuOvhrUP++B/jQBxXalrsj8MfGi/e8Najn/cH+NRt8N/GCn5vDmoD/tnQByI5FIK6eXwH4qiGX0DUAB/0yNVZfCfiCH/W6Nfr1x+5NAGGaTFacmh6rG2H0y+H/bBv8KjOlaiB81hdj6wt/hQBRxSADFWmsbtcb7WdfrG3+FRGKRThonHsVNAEWKTGKcQRz0o6UANpaM0lABilxSUtACCg0tIKAFpKOtGKAClpOmKAaAFo7UZ6UUAJS9qSjtQAp60YopO2BQAUUZ55ooASgdaB0ooAXPSlIpM5pTmgAxQaO1FAB0oFFJ2JoAKKKKAClB44pKBmgB4ZgcgkH24qxFqV9EoEV5coB2WVh/Wqo60p60AaUeu6umAmqXygcACdxj9at2Hi7xFYSeZaa1fxvjGfPY8cev0FYNAoA7WH4o+NIsbPEV/+L5q3F8X/AB4ibU8S3o/75/wrgOvag0Aeip8ZvHwIz4jum78hf8KsRfG7x6jBjrbNj+9GpFeZelKCc8mgD1ZPjx46Xbm+tnx/etwasR/tA+N1GGfTHGc/NaD/ABryHJoBO6gD2NP2hPGGcvDpLev+igf1qWL9oPxJtYTafpUgIx/qMYrxck4FH0oA9uH7QWpM377w5pEo9CpH9KP+F9b+ZvBmiOfXJH9K8R9qSgD2dfjVYscy+B9FI7AZP9KlHxg8PSH/AEnwHpp4/gArxLPFGaAPbz8UfAkoP2jwDGf9wqMVDJ4/+GUsZD+AZgc9pFrxce5pPrQB7V/wl/wmmyH8G3MXoVYf0pn9ufCKXO7Qr6LPpk14vmigD2b7X8HJBhoNVj9xGTUDw/B+Y5W61eIA/wDPM815B0ozQB7AmkfCSU/JrOpR+m9TUx8J/CuVcx+LriM/7S14znNGc9aAPXm8DfDt2HleOwuf7yCj/hXXgpmCw+O4GzjBKCvIaO3agDtNY8PaVZW14LXUIbkQtIiSr1cKThvxA/WmHwZF/wAK8XxONYs/MJ/48dw83/W+X0/8e+lcn9ok8oR7vlxj8KixQB1HgzwxD4hmu4pr+O1eKNXj3Yw2Tg5/Su3/AOFLysGEeu6dnnln/KvIkdkOUYqcYyDUwvLkLgTygdMbzQBHcwm3uJYWZWaN2QshypIOMg+lM6ikpaAG/lRS8d6KAEFH40gpaAAZp3cU3PSgHmgBxoNNJNLnj3oAPrUsFvNPuEEMkm3GdilsflUWeldX4T8f694V06Sx0aa3igkmM77oFdmYqFwSecYXp9fWgDnxpt8RxZXJHqIm/wAKDpl8oy1ncj6xN/hXdL8Y/Fqgfv7NgBjm2XmoW+LXiktlprNvY24xQBwz286f6yGVT7oRUWQOO9el2vxd1NVIvNJ0q6PHLRYq7H8ZHj2f8Un4fdVJzugyW+bPX6ZH45oA8nH6UpAr1z/hdAIXd4K8NkjALCHGemac3xmiZSP+EL8Pg9chD6/SgDyEYoB56ivUn+LUchIfwlopQ8424wfyrUtviP4IkAOpeDmdiTnyjGB7dfagDxoY9cUDHJzxXs//AAnXwuL5bwDcOcYz5iUDx58LUTA+HcrE9MzLQB4zkc0Ej1r22Pxn8JJZNsvgeaFTk7t+fT3p7a58GpZpc6DexoMbSqtz+tAHh4GecH8qOAa9thuvgs8r+amrQx7eMROefzqO4i+CUwAju9aQ9MiFx7f40AeLDB/lSYwOte2w6V8FZQx/tXVUw20Btwzz1+lOHhv4PzqDB4hu4s/89Wxjp7e/6GgDxDHfNJXtg8G/CyUjZ4y8oEA/M3T9KZdeAPhwFzH8Qbf6ZB/pQB4tijHpXro+HvgV9oXx/b5PbaDj/PFWE+FvhGRcw+ObdsHHKjrz/hQB4zSjp1r2ZvhBorShIPGVi2TgZK89Pf3pp+C0JDFPFelbR0LOo/rQB4yRzzR1r19vgrKxBh8T6MRyOZR1/Om/8KP1EkbNf0Ziewl/+vQB5FRXrTfA3XsZj1HTJAem2XrWHr3w01Hw9c2serT2/wDpKSNH5b5zsK5/9DFAHA0ldBF4Xvby+1WDT1WRdNs2vpizYxEoBYj1PPSo/DXh26169mtbd0jkSBphv6NgrwPf5hQBiCivTLj4PeIC6i2W2IPXM319fpXCeINGuvD+sXGmagqi5g27wrbh8yhhz9GFAGdS0dqO9ACGlpO9AoAUUdqQ0UAAzRSA80UAFJS0lACilPWko70AKfeg/doNHagBO9ApB9aWgBe1FID0oHSgBaBxQTRnvQAA80oopAKAF70vNJSZxQA7NGTzSZ60ZyaAHAnPWgMc0neigBQcAHFKD1zTMcUD1BoAXdg0A8ik6UGgBc96CaSjPXFAC59KTtSZNGT2oAXtijrSYpelAACR0JFSLPMpBSaRcejmos0A0AW11G+QfLeXIx6SsP607+1LxpVkmuJpioIXzJC23OOmenQVSFGeaALL3lw00sqzSI0qeW+1iNy4wQfUcdKZb3U9s5e3mkiYgglGI4P/AOoflUXeigDVPiPWCuDqNzj/AK6Gs+6uJru4aa5kaWVsbnY5JwMfyqLvRQAgo+lLn8qBQAUn8qWkHAoAMfnQcUGjNAAKKUUUAMooP60GgApaTFL3oAD3oPQUGjtQAd6KB60UAA60nalooAKBxRSdqAFzyKXNNFLQA4UlItL2oAKOlHvSjmgBO1ANLSUALmgHpSEUUAGaBRS0AJRilo70AGKKTPNIaAHZppNHaigApM8UUUAKOtO700dKBnP4UAKOtFHfrS9hQAZ6UUelJk0AKKO1IDS0AFH4Ug45o68dqADrSnpSd6O+KADIFFAooATvSetGKWgBKWiigANHb2pKXtQAUtIKWgBKO9FFABRRij0oAOlJS0UAIOtLRSUAL2ozSUvagBQeaAeRTaAOaAHmgUelIPrQAZoHTikNIOvFAC0GiigA7UUlFAC0ntRR3oAKKU9KSgBRQKKOlAATS0lHvQAueBR3pPSgdKACl6Y5pKUYoAUU3PFL6UnWgBTQPekNL1oAQHHSige9FAHtX/CqtD/5+tS/7+J/8RR/wqrQ/wDn61L/AL+J/wDEUUUAJ/wqrQ/+frUv+/if/EUf8Kq0P/n61L/v4n/xFFFAB/wqrRP+frUv+/if/EUf8Kq0P/n61L/v4n/xFFFAC/8ACqtD/wCfrUv+/if/ABFH/CqtD/5+tS/7+J/8RRRQAf8ACqtE/wCfrUv+/if/ABFH/CqtE/5+tS/7+J/8RRRQAf8ACqtDz/x9al/38T/4ij/hVWh/8/Wpf9/E/wDiKKKAD/hVWh/8/Wpf9/E/+Io/4VVof/P1qX/fxP8A4iiigBD8KtD/AOfrUv8Av4n/AMRSj4VaH/z9al/38T/4iiigA/4VVof/AD9al/38T/4ik/4VVof/AD9al/38T/4iiigBT8KtD/5+tS/7+J/8RR/wqrQ8/wDH1qX/AH8T/wCIoooAD8KtD/5+tS/7+J/8RR/wqrQ8f8fWpf8AfxP/AIiiigBB8KtDwf8AStS/7+J/8RR/wqrQ/wDn61L/AL+J/wDEUUUAL/wqrQ/+frUv+/if/EUf8Kq0P/n61L/v4n/xFFFAB/wqrQ+P9K1L/v4n/wARSH4VaH/z9al/38T/AOIoooAP+FVaH/z9al/38T/4il/4VVoeP+PrUv8Av4n/AMRRRQAn/CqtD/5+tS/7+J/8RS/8Kq0P/n61L/v4n/xFFFACf8Kq0PP/AB9al/38T/4il/4VVof/AD9al/38T/4iiigBB8KtD/5+tS/7+J/8RS/8Kq0PH/H1qX/fxP8A4iiigBD8KtDz/wAfWpf9/E/+Ipf+FVaH/wA/Wpf9/E/+IoooAP8AhVWh4/4+tS/7+J/8RS/8Kq0PP/H1qX/fxP8A4iiigAHwq0P/AJ+tS/7+J/8AEUn/AAqrQ+P9K1L/AL+J/wDEUUUAH/CqtE/5+tS/7+J/8RQfhVomP+PrUv8Av4n/AMRRRQAf8Kq0QD/j61L/AL+J/wDEUUUUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    12 mm Efer-Dumon bronchoscope (rigid tubes only) for use in bronchi (long tube) or trachea (short tube).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Henri G Colt, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_31_25085=[""].join("\n");
var outline_f24_31_25085=null;
var title_f24_31_25086="Number of risk factors and CVD risk";
var content_f24_31_25086=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F55353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F55353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Additive effects of risk factors on cardiovascular disease at five years",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 393px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cumulative absolute risk of cardiovascular disease (CVD) at five years according to systolic blood pressure and specified levels of other risk factors. The reference category is a nondiabetic, nonsmoking 50-year-old woman with a serum total cholesterol (TC) of 154 mg/dL (4.0 mmol/L) and HDL-cholesterol of 62 mg/dL (1.6 mmol/L). The CVD risks are given for systolic blood pressure levels of 110, 130, 150, and 170 mmHg. In the other categories, the additional risk factors are added consecutively. As an example, the diabetes category is a 50-year-old diabetic man who is a smoker and has a total cholesterol (TC) of 270 mg/dL (7 mmol/L) and HDL-cholesterol of 39 mg/dL (1 mmol/L).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Jackson R, Lawes CM, Bennett DA, et al, Lancet 2005; 365:434.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_31_25086=[""].join("\n");
var outline_f24_31_25086=null;
var title_f24_31_25087="Penis being prepped";
var content_f24_31_25087=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Penis being prepped",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David G Weismiller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_31_25087=[""].join("\n");
var outline_f24_31_25087=null;
